Document:

bntx-ex452_415.htm

Exhibit 4.52

 

SENSITIVE

 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN

IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM

THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND

(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE

COMPANY IF PUBLICLY DISCLOSED

 

	

	
EUROPEAN COMMISSION
Directorate-General for Health and Food Safety

 

PURCHASE AGREEMENT (“PA”)1 for the further development, production, 
purchasing options and supply of the successful COVID-19 Vaccine for EU Member
States

NUMBER — [complete]

1.The European Commission, acting on behalf and in the name of the Member States set out in Annex III (hereinafter referred to as “Participating Member States”),2:

being represented for the purposes of the signature of this PA by Ms Stella Kyriakides, Commissioner of Health and Food Safety

on the one part and

2.Pfizer Inc.

Incorporated in Delaware (Registration Number 0383418) with its registered address at 235 East 42nd Street

10017 New York City, NY (UNITED STATES)

appointed as the leader of the group by the members of the group that submitted the joint tender

(hereinafter referred to as “Pfizer”)

and

BioNTech Manufacturing GmbH

Registered with the commercial register of the lower court (Amtsgericht) of Mainz, Germany under HRB 47548, with its registered address at An der Goldgrube 12

 

	
	 

	
1  
	
This PA is based on the agreement between the Commission and the Member States as approved by Commission Decision C(2020) 4192 final on approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures.

	
2  
	
As provided for in Article 4(5)(b) of Council Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency support within the Union as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID‐19 outbreak.

 

 

 

55131 MAINZ, GERMANY

(hereinafter referred to as “BioNTech”)

as a member of the group (collectively ‘the Contractor’), represented for the purposes of the signature of this PA which has the form of a framework contract by [***].

on the other part,

 

HAVE AGREED

 

to the special conditions and the general conditions of this PA and the following Annexes and Attachments:

Annex I – Model for Vaccine Order Form

Annex II – Agreement between the Commission and Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures, annexed to the Commission Decision C(2020) 4192 final of 18 June 2020

Annex III – Participating Member States

Annex IV – Subcontractors

Annex V – Participating Contractor Affiliates

Attachment 1 – Specifications

Attachment 2 – Delivery Documentation

Attachment 3 – Delivery Specification

Attachment 4 – Labelling and Packaging Specifications

Attachment 5 – Return and Disposal of Product Materials

which form an integral part of this PA. 

[***].

This PA sets out:

	
 
	
1.
	
the procedure and conditions by which the Participating Member States will pay for the services and/or supplies from the Contractor;

	
 
	
2.
	
the provisions that apply to any Vaccine Order Form which the Participating Member States and the Contractor may conclude under this PA; and

	
 
	
3.
	
the obligations of the parties during and after the duration of this PA.

 

 

	
 
		

All documents issued by the Contractor (end-user agreements, general terms and conditions, etc.) except its tender are held inapplicable, unless explicitly mentioned in the special conditions of this PA. In all circumstances, in the event of contradiction between this PA and documents issued by the Contractor, this PA prevails, regardless of any provision to the contrary in the Contractor’s documents.

 

 

 

 

 

Table of Content

 

	
TABLE OF CONTENT
	
4

	
I.
	
SPECIAL CONDITIONS
	
6

	
I.1
	
Order of Priority of Provisions
	
6

	
I.2
	
Definitions
	
6

	
I.3
	
Subject Matter
	
10

	
I.4
	
Entry into force and duration of the APA
	
11

	
I.5
	
Implementation of the APA
	
11

	
I.6
	
Supply of the Vaccine
	
12

	
I.7
	
Prices
	
16

	
I.8
	
Payment Arrangements
	
16

	
I.9
	
Communication Details
	
18

	
I.10
	
Project management
	
18

	
I.11
	
Exploitation of the results of the APA
	
18

	
I.12
	
Indemnification
	
18

	
I.13
	
Applicable Law and Settlement of Disputes
	
18

	
I.14
	
Other Special Conditions
	
18

	
II.
	
GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT FOR SERVICES
	
20

	
II.1
	
Definitions
	
20

	
II.2
	
Roles and responsibilities in the event of a joint tender
	
20

	
II.3
	
Severability
	
20

	
II.4
	
Provision of services and supplies
	
20

	
II.5
	
Communication between the parties
	
20

	
II.6
	
Liability
	
21

	
II.7
	
Conflict of interest and professional conflicting interests
	
22

	
II.8
	
Representations and warranties
	
23

	
II.9
	
Confidentiality
	
24

	
II.10
	
Announcements and publicity
	
25

	
II.11
	
Processing of personal data
	
26

	
II.12
	
Subcontracting
	
26

	
II.13
	
Amendments
	
26

	
II.14
	
Assignment
	
27

	
II.15
	
Force majeure
	
27

	
II.16
	
Suspension of the implementation of the APA
	
27

 

 

	
II.17
	
Termination of the APA
	
28

	
II.18
	
Invoices, value added tax and e-invoicing
	
29

	
II.19
	
Payments and guarantees
	
30

	
II.20
	
Recovery
	
31

	
II.21
	
Checks and audits
	
31

	
II.22
	
Relationship of the parties
	
33

	
II.23
	
Waiver
	
33

	
II.24
	
Further documents
	
33

	
II.25
	
Headings
	
33

	
II.26
	
Electronic Delivery and Storage
	
33

	
II.27
	
Entire Agreement
	
33

	
II.28
	
Costs
	
33

	
ANNEX I: MODEL FOR VACCINE ORDER FORM
	
34

	
ANNEX II: AGREEMENT BETWEEN THE COMMISSION AND MEMBER STATES ON PROCURING COVID-19 VACCINES ON BEHALF OF THE MEMBER STATES AND RELATED PROCEDURES, ANNEXED TO THE COMMISSION DECISION C(2020) 4192 FINAL OF 18 JUNE 2020
	
39

	
ANNEX III: PARTICIPATING MEMBER STATES
	
44

	
ANNEX IV: SUBCONTRACTORS
	
45

	
ANNEX V PARTICIPATING CONTRACTOR AFFILIATES
	
46

	
ATTACHMENT 1: SPECIFICATION
	
47

	
ATTACHMENT 2: DELIVERY DOCUMENTATION
	
48

	
ATTACHMENT 3: DELIVERY SPECIFICATION
	
49

	
ATTACHMENT 4 : LABELLING AND PACKAGING SPECIFICATIONS
	
50

	
ATTACHMENT 5: RETURN AND DISPOSAL OF PRODUCT MATERIALS
	
51

 

 

 

 

 

I.Special Conditions 

I.1Order of Priority of Provisions

If there is any conflict between different provisions in this PA, the following rules must be applied:

	
 
	
(a)
	
The provisions set out in the special conditions and Article II.6 of the general conditions (Liability) take precedence over those in the other parts of the PA.

	
 
	
(b)
	
The other provisions set out in the general conditions take precedence over those in the Annexes and Attachments.

	
 
	
(c)
	
The provisions set out in the PA take precedence over those in the Vaccine Order Forms.

I.2Definitions

The following definitions shall apply to this PA:

‘Additional Order’: has the meaning set forth in Article I.6.2;

‘Additional Product’: has the meaning set forth in Article I.6.2;

‘Affiliate’: means in relation to a body corporate, any other entity which directly or indirectly Controls, is Controlled by, or is under direct or indirect common Control of that body corporate from time to time;

‘Authorisation’: means a Conditional Marketing Authorisation and/or Marketing Authorisation that permits the Products to be placed on the market in the European Economic Area;

‘Best Reasonable Efforts’: [***];

‘Conditional Marketing Authorisation’: means a conditional marketing authorisation granted by the European Commission as referred to in Article 14-a of Regulation (EC) No 726/2004;

‘Confidential Information’: means any information disclosed to or obtained by one party to the other party, either directly or indirectly, or which the disclosing party indicates in writing at the time of disclosure to, or receipt by, the recipient is to be considered confidential or proprietary, or which such recipient knows or ought reasonably to know is information of a confidential or proprietary nature, including the terms of this PA and any Vaccine Order Form. Confidential Information shall not include any information (i) the receiving party can prove was known to it prior to the date of disclosure; (ii) the receiving party can prove was lawfully obtained from a third party without any obligation of confidentiality; (iii) is or becomes part of the public domain other than through any act or omission of the receiving party; or (iv) is independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as evidenced by the receiving party’s records;

 

 

‘Conflict of interest’: a situation where the impartial and objective Implementation of the PA by the Contractor is compromised for reasons involving family, emotional life, political or national affinity, economic interest, any other direct or indirect personal interest, or any other shared interest with the Commission, the Participating Member State or any third party related to the subject matter of the PA;

‘Contracted Doses’: has the meaning set forth in Article I.6.2;

‘Control’: means the possession by a person or an entity, directly or indirectly, of the power to direct or cause the direction of the management and policies of the other person or entity (whether through the ownership of voting shares, by contract or otherwise) and "Controls" and "Controlled" shall be interpreted accordingly;

‘Delivery Price’: has the meaning set forth in Article I.8.2;

‘Delivery Schedule’: has the meaning set forth in Article I.6.3

‘Effective Date’: has the meaning set forth in Article I.4.1;

‘Force majeure’: any unforeseeable, exceptional situation or event beyond the reasonable control of the parties that prevents either of them from fulfilling any of their obligations under the PA [***];

‘Formal notification’ (or ‘formally notify’): form of communication between the parties made in writing by mail or email, which provides the sender with compelling evidence that the message was delivered to the specified recipient;

‘Fraud’: an act or omission committed in order to make an unlawful gain for the perpetrator or another by causing a loss to the Union's financial interests, and relating to: i) the use or presentation of false, incorrect or incomplete statements or documents, which has as its effect the misappropriation or wrongful retention of funds or assets from the Union budget, ii) the non-disclosure of information in violation of a specific obligation, with the same effect or iii) the misapplication of such funds or assets for purposes other than those for which they were originally granted, which damages the Union's financial interests, it being understood that the Union’s financial interests are impacted within the framework of this PA as the Union is engaging resources into the coordination and preparation of the PA, resulting from Decision C(2020) 4192 final of 18 June 2020 which approved the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States (“the Decision”), this agreement being based on Article 4(5)(b) of Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency support within the Union3 (“the ESI Regulation”) ;

‘Good Manufacturing Practice’: means the current practices for manufacture required by the standards, rules, principles and guidelines set out in Directive 2001/83/EC (as amended by Directive 2004/27/EC), Directive 2017/1572, Directive 2003/94/EC and EudraLex - Volume 4 of the Rules Governing Medicinal Products in the EU entitled “EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use”;

	
	 

	
3  
	
OJ L 70, 16.3.2016, p.1, as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID‐19 outbreak, OJ L 117, 15.4.2020, p. 3.

 

 

 

‘Implementation of the PA’: the purchase of services or supplies envisaged in the PA through the signature and performance of Vaccine Order Forms;

‘Indemnified Persons’: has the meaning set forth in Article I.12.1;

‘Irregularity’: any infringement of a provision of Union law resulting from an act or omission by the Contractor within the meaning of Article 1(2) of the Council (EC, Euratom) Regulation 2988/95 of 18 December 1995 on the protection of the European Communities financial interests (in OJ 23.12.95, L 312/1) , which has, or would have, the effect of prejudicing the Union’s budget, it being understood that the Union’s financial interests are impacted within the framework of this PA, as the Union is engaging resources into the coordination and preparation of the PA, resulting from the Decision which approved the agreement with Member States on procuring COVID-19 vaccines on behalf of the Member States, this agreement being based on Article 4(5)(b) of the ESI Regulation;

[***]

‘Latent Defect’: means a defect causing the Product to not conform to the applicable Specifications that the relevant Participating Member State can show was present at the time of delivery of the Product and which could not have been detected by the Participating Member State, its designee, or their personnel at delivery through visual inspection;

‘Law(s)’: means, collectively, all applicable supranational, national and local laws, common laws, statutes, ordinances, codes, rules, regulations, orders, decrees or other pronouncements of any government, administrative or judicial authority having the effect of law;

‘Losses’: has the meaning set forth in Article I.12.1;

‘Marketing Authorisation’: means the marketing authorisation (other than Conditional Marketing Authorisation), in respect of the Product granted by the European Commission, as amended or varied from time to time, that allows the Product to be placed on the market in the European Economic Area according to applicable Law;

‘Non-Complying Product’: has the meaning set forth in Article I.6.14;

‘Notification’ (or ‘notify’): form of communication between the parties made in writing including by electronic means;

‘Participating Contractor Affiliate’: means an Affiliate of Pfizer or BioNTech as identified in Annex V;

‘Product’: means the Vaccine;

‘Product Materials’: means all packaging materials and components needed for delivery of the Product;

‘Professional conflicting interest’: a situation in which the Contractor’s previous or ongoing professional activities affect its capacity to implement the PA or to perform a Vaccine Order Form to an appropriate quality standard;

 

 

‘Record’: means books, documents, and other data, of all matters relating to performance of obligations under this PA;

‘Related person’: any natural or legal person who is a member of the administrative, management or supervisory body of the Contractor, or who has powers of representation, decision or control with regard to the Contractor;

‘Specifications’: means the specifications for the manufacture, testing and testing procedures, and supply of the Product as set out in Attachment 1 (Specifications), and as such specifications may be amended, supplemented or otherwise modified by the Contractor and communicated to the Commission;

‘Taxes’: has the meaning set forth in Article II.18.1;

‘Term’: means the term of the PA set out in Article I.4.2 of the PA; 

‘Thermal Shipper’: has the meaning set forth in Article I.6.8; 

‘Third Party Claim’: has the meaning set forth in Article I.12.4.

‘Vaccine’: the medicinal product, being BNT162b2, a nucleoside-modified messenger RNA (mRNA) vaccine that encodes an optimized SARS-CoV-2 full-length spike glycoprotein (S) for which Authorisation has been granted, including any subsequent variations approved by the Commission. [***].

‘Vaccine IP Rights’: has the meaning set forth in Article I.11; and

‘Vaccine Order Form: has the meaning set forth in Article I.5.2.

Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation", (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person's successors and assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this PA in its entirety and not to any particular provision hereof, (g) all references herein to Articles, Annexes or Attachments shall be construed to refer to Articles, Annexes or Attachments of this PA, and references to this PA include all Annexes and Attachments hereto, (h) the word “notice” means notice in writing or by email (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this PA, (i) provisions that require that a party or parties “agree”, “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (including e-mail), (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof.

 

 

I.3Subject Matter

The subject of the call for tenders SANTE/2021/C3/005 is securing the purchase of certain vaccine doses for the Participating Member States.

Following the Decision, taken in accordance with Article 4(5)(b) of the ESI Regulation, the Commission is running procurement procedures on behalf of Participating Member States, with a view to signing EU-level Advance Purchase Agreements (“APAs”) with vaccine manufacturers. 

An APA between the Parties was signed on 20 November 2020. 

In compliance with Article 164(l)(d) as well as Annex I, Point 11.1(c) of the Financial Regulation, the Commission launched on 12 January 2021 a negotiated procedure without prior publication of a contract notice for the procurement of additional doses of vaccines. This procedure was justified by the need to quickly secure additional doses of vaccines to reach a turning point in the epidemic. This PA is for such additional doses, and while it is organised following the Decision it is entirely separate from the APA between the Parties.

In view of its importance, this PA will be approved for signature on behalf and in the name of the Participating Member States by a separate individual Commission decision.

The Conditional Marketing Authorisation for the Vaccine was granted on 21 December 2020.

The Commission, on behalf of the Participating Member States, wishes to purchase the Vaccine during the pandemic period through this PA. 

On the basis of this PA, the European Commission commissions the Contractor to commit to produce and deliver 200 million doses of the Vaccine which shall be ordered by the Participating Member States (via specific Vaccine Order Forms) at the price and conditions, including timeframe, agreed under this PA, with the option to obtain a further 100 million doses of the Vaccine subject to the conditions set out in this PA.

The Contractor or a Participating Contractor Affiliate shall supply to the Participating Member States the agreed doses of the Vaccine pursuant to the Vaccine Order Forms. 

The Vaccine Order Forms shall be signed by the Contractor and shall incorporate by reference this PA.

I.4Entry into force and duration of the PA

	
I.4.1
	
The PA enters into force on the date on which the last party signs it (“Effective Date”).

	
I.4.2
	
The PA is concluded for a period of eighteen (18) months with effect from the Effective Date (“Term”).

	
I.4.3
	
Contractor and the Participating Member States may not sign any Vaccine Order Form after the PA expires.

The PA continues to apply to such Vaccine Order Forms after its expiry. [***].

 

 

	
I.4.4
	
Renewal of the PA 

The PA will expire automatically at the end of the Term, unless it is extended in mutual written agreement between the parties. Renewal does not change or postpone any existing obligations.

I.5Implementation of the PA 

I.5.1Period of provision of the supplies

The period for the provision of the supplies starts to run as foreseen in Article I.6.3. 

I.5.2Implementation of the PA

The PA shall be implemented following signature between the Commission and the Contractor as follows:

The Contractor shall use Best Reasonable Efforts to obtain manufacturing capacity or utilise existing capacity to be capable of manufacturing and supplying the Product to the Commission on behalf of the Participating Member States in accordance with the provisions of this PA.

The Contractor agrees to supply an initial total number of 200 million Vaccine doses to Participating Member States collectively, upon their order, in accordance with this PA and the respective Vaccine Order Forms.

The Participating Member States shall place orders for supplies of 200 million Vaccine doses in total in accordance with the allocation communicated by the Commission to the Contractor pursuant to Article I.6.3, by sending the Contractor a completed copy of Annex I (“Vaccine Order Form”) in paper format or emailed pdf [***]. This Vaccine Order Form shall be signed by an authorised representative of the Participating Member State and the Contractor.

[***] the Contractor must send back to the Participating Member States the duly signed and dated Vaccine Order Form in paper format or emailed pdf.

I.6Supply of the Vaccine

	
I.6.1
	
General

During the term of this PA, the Contractor shall supply or have supplied the Product to the relevant Participating Member States, and the Participating Member States shall purchase the Product, subject to and in accordance with the terms and conditions of this PA.

	
I.6.2
	
Product supply

At the Effective Date, the Commission orders 200 million doses (“Contracted Doses”) of the Product on behalf of the Participating Member States [***] according to the terms laid down in this PA. 

 

The parties acknowledge that the Commission may wish to place an ‎additional binding order (the “Additional Order”) for a maximum ‎of up to 100 million doses of the Vaccine. The parties also agree that such Additional Order may be placed by the Commission only after (i) being advised by the Contractor that ‎the Contractor has availability of supply of such additional requested doses at the time of the proposed Additional Order (the ‎‎“Additional Product”) (ii) 

 

 

the Contractor agrees, in its sole discretion, to ‎allocate the Additional Product to the Commission (iii) the Contractor confirms how many doses can be delivered and by when (iv) the Commission confirms the required allocation between Participating Member States and (v) [***]. The Additional Order will be ‎placed by way of an additional Vaccine Order Form and, as such, be ‎subject to the same terms and conditions set forth in this PA. [***].

The Commission shall communicate to the Contractor the allocation of the Contracted Doses supplied pursuant to the initial order and any Additional Product among the governments of the Participating Member States. [***] 

[***]

 

	
I.6.3
	
Supply mechanism

Vaccine supply in Europe will primarily come from [***] manufacturing site [***] and shall incorporate RNA produced at [***] manufacturing sites including sites operated by the following sub-contractors:

 

[***]

 

The Delivery Schedule is as follows (subject to the limitations set forth below):

 

	
Quarter
	
[***]
	
[***]
	
[***]

	
Doses (million)
	
[***]
	
[***]
	
[***]

 

The Delivery Schedule and logistics will be further refined [***] by the Contractor after the Commission has communicated how to apportion the 200 million Vaccine doses amongst the Participating Member States pursuant to the provisions of this Article I.6.3. [***].

	
 
	
(i)
	
[***]

	
 
	
(ii)
	
[***]

For the avoidance of doubt, the Participating Member States will not have the right to terminate the Vaccine Order Forms [***] in the event that the Commission has not exercised its right to terminate the PA. 

The Contractor shall use Best Reasonable Efforts to ensure that the doses are supplied in accordance with the Delivery Schedule, the estimated monthly and weekly schedules and the dates set out in the Vaccine Order Forms. [***] Allocations shall be made pursuant to Article I.6.3(i) in case of insufficient supply to deliver the full amount of Contracted Doses. 

Within [***] following the Effective Date, the Commission shall communicate to the Contractor a table how to allocate the 200 million Vaccine doses amongst the Participating Member States. 

Each Participating Member State shall have a commitment to purchase the number of Vaccine doses as set out in the above-mentioned allocation table and to sign a Vaccine Order Form to this effect as set out below. 

 

 

To operationalise the ordering of the Vaccine, each Participating Member State will enter into a Vaccine Order Form. Each Vaccine Order Form will specify in particular the number of doses that the Participating Member State will purchase from the above-mentioned allocation table, the price of all Vaccine doses pursuant to Article I.7, and the liability and indemnification undertakings by the Participating Member State (which will be incorporated by reference from the PA into the Vaccine Order Form). [***] For the avoidance of doubt, the Contractor shall have no obligation to supply any Vaccine doses to any Participating Member State where there is not a Vaccine Order Form, including provisions related to liability and indemnity (which will be incorporated by reference from the PA into the Vaccine Order Form executed by the Participating Member State and the Contractor). It is agreed that the Contractor may discharge its obligations under the Vaccine Order Form acting with one or more Participating Contractor Affiliates.

	
I.6.4
	
Manufacturing

The Contractor confirms that it is in possession of all necessary manufacturing authorisations to undertake the manufacturing of the Vaccine. 

	
I.6.5
	
Legal and regulatory filings and requests

The Contractor shall ensure that all Product is properly labelled and packaged in accordance with the provisions of Article I.6.8 and Good Manufacturing Practice and in accordance with the applicable EU legislation on information on packaging (Title V of Directive 2001/83/EC). 

Notwithstanding the above, [***] the Contractor shall comply with all conditions (in the relevant timescales) set out in the Authorisation (where applicable), subject to any exemption, exception or waiver of requirements for the Product granted or permitted by the Participating Member State (including but not limited to serialization).

	
I.6.6
	
Clinical trials and licensure

[***]

	
I.6.7
	
Waiver

The Commission acknowledges and agrees that the Contractor’s efforts to continue to develop and manufacture the Vaccine are aspirational in nature and subject to significant risks and uncertainties. Notwithstanding the efforts and any estimated dates set forth in this PA, the parties acknowledge that the Vaccine might not be delivered fully according to the Delivery Schedule due to technical, clinical, regulatory or manufacturing, shipping, storage or other challenges or failures.

[***] 

	
I.6.8
	
Packaging, labelling and shipping

At the date of execution of this PA, the Vaccine is expected to be supplied in a thermal shipping box in accordance with Attachment 4 (Labelling and Packaging Specifications) (“Thermal Shipper”). [***]. The costs of packaging, packing materials, addressing, labelling, loading and delivery to the agreed Participating Member States’ delivery point of the Vaccine [***].

 

 

All deliveries shall be accompanied by the documentation specified in Attachment 2 (Delivery Documentation) (which may be updated from time to time by the Contractor upon notice to the Commission), and shall be in accordance with, and subject to, the delivery specification set forth in Attachment 3 (Delivery Specification). The Product shall be labelled and packaged in accordance with the packaging specifications set forth in Attachment 4 (Labelling and Packaging Specifications). 

Final specifications including package size and labels will be communicated to the Commission and to the Participating Member States prior to delivery. All specifications shall be consistent with any conditions set out in the Authorisation and applicable Law.

	
I.6.9
	
Storage, transport and product acceptance

[***]

[***] Final storage specifications, based on the Authorisation received, will be communicated to the Participating Member State prior to delivery. 

	
I.6.10
	
Delivery

The Contractor will deliver the doses ordered by each of the Participating Member States to one or more locations selected by the Participating Member State in accordance with the procedure set out in this Article I.6.10 and the Vaccine Order Form. [***] For the avoidance of doubt, the Participating Member States shall bear all costs and expenses for operating these distribution hubs and for use of the Vaccine, including, but not limited to, those for storage and distribution of the Vaccine after delivery, local duties and local QA testing.

The duly authorised representative of the Participating Member State shall sign to confirm receipt of delivery (the current proposed format of which is as set out in Attachment 2 (Delivery Documentation)). The person signing for receipt must ensure the contents of the delivery match the accompanying shipping documentation proof of receipt.

The Contractor shall deliver the Product [***] to the location agreed pursuant to this Article I.6.10. 

The Contractor and the Participating Member State shall agree the location(s) for delivery of shipments of the Product; provided that (i) each location meets the requirements set forth in Attachment 3 (Delivery Specification), and (ii) all locations which are additional to those approved in advance by the Contractor prior to the Effective Date shall be agreed upon by the Contractor and the Participating Member State at least [***].

All shipments of Product [***], or such other amount as notified to the Commission from time to time by the Contractor in accordance with the terms of this PA. 

	
I.6.11
	
Product handling

Upon delivery of the Product, the Participating Member State shall store and handle the Product in the manner set forth in the Specifications set forth in Attachment 1 (Specifications), instructions in Attachment 3 (Delivery Specification) and the instructions provided by the Contractor to ensure stability and integrity of the Product. 

 

 

The Participating Member States shall be solely responsible and liable for the proper storage, handling, distribution, transportation, administration, use and disposal of the Product in their [***] following delivery of the Product to the Participating Member State or its designee. Without prejudice to the generality of the foregoing, the Participating Member States ensure that: (a) recipients of the Product shall follow the return and disposal instructions in Attachment 5 (Return and Disposal of Product Materials) (as updated by the Contractor and communicated to the Participating Member State from time to time) when disposing of open and unused Product and its packaging components; and (b) such return and disposal complies with Laws regarding pharmaceutical waste, medical waste, or hazardous waste, as appropriate.

Participating Member States shall be responsible for and shall ensure that any equipment used to deliver the Product, for example [***], are stored in an appropriate clean and secure location to protect and maintain the functionality of such equipment (in controlled conditions, with no exposure to weather or pests, etc). Within [***] of receipt of the Product, subject to Article I.6.14, the Participating Member State shall take the necessary measures to enable the collection by the Contractor of all such equipment, including [***], in accordance with the Contractor’s instructions, consistent with the provisions of Attachment 5 (Return and Disposal of Product Materials).

The Contractor may provide Safety Data Sheets and other agreed information to Participating Member States [***]. 

[***]

	
I.6.12
	
Title to Product and risk of loss

[***]

	
I.6.13
	
Quality tests and checks

[***]

	
I.6.14
	
Rejection of Product; Disposal of rejected shipments

A Participating Member State must visually inspect the Product [***] following the instructions set out in Attachment 3 (Delivery Specification) and may reject any specific delivery of the Product or doses therein that does not conform [***] (“Non-Complying Product”) by providing notice to Pfizer Customer Service following an agreed protocol: [***]. 

[***]

Without prejudice to the right to refer the matter to the dispute resolution procedure set out in Article I.13.2 and the provision on [***], replacement of Non-Complying Product [***]. The provisions of this Article I.6.14 shall survive termination or expiration of this PA.

	
I.6.15
	
Maintenance and retention of Records

Each party shall maintain [***] with respect to its activities under this PA as required by Laws.

The Participating Member State will maintain a quality system for receipt, inspection, storage, traceability to further delivery points, and recall activities. If the Participating Member State 

 

 

does not have a quality system for the activities defined, the Contractor may share details of a proposed quality system for the Participating Member State’s compliance. 

	
I.6.16
	
Diversion issues

All Product delivered to a Participating Member State shall be: (a) stored securely by the Participating Member State; and (b) without prejudice to Article I.6.2, distributed by the Participating Member State in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorised resale or export out of the Participating Member State, and to protect and preserve the integrity and efficacy of the Product. [***].

I.7 Prices

The price of the Vaccine to the Commission and the Participating Member States for the 200 million Contracted Doses and any Additional Order will be [***]. 

I.8 Payment Arrangements

I.8.1 [***]

I.8.2 Delivery Price

The Delivery Price for the Contracted Doses and any Additional Order is to be paid by the Participating Member State to the Participating Contractor Affiliate [***]. [***] 

[***]

The Participating Contractor Affiliate may claim the payment of the balance in accordance with Article I.8.2. The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf for payment of the balance due under a Vaccine Order Form for each provision of supplies to the Participating Member States.

Invoices shall be established by the Participating Contractor Affiliate for a given order of supplies and for an identified delivery scheduled within the Vaccine Order Form.

The Participating Contractor Affiliate may not send an invoice to a Participating Member State before it receives from the Participating Member State [***] in respect of which such invoice is established, which [***].

The Participating Contractor Affiliate must send an invoice in paper format or emailed pdf or by electronic systems for payment due under the Vaccine Order Form accompanied by the following:

[***]

Each invoice must contain the following information:

-Name of the Participating Member State concerned
-PA and Vaccine Order Form number/reference
-Order reference

 

 

-Billing address
-Product [***]
-Quantity [***]
-[***] reference and date

-Price

-Any applicable taxes, transportation charges or other charges provided for in the Vaccine Order Form

-The ship-to destination

-[***]
-Participating Contractor Affiliate name and bank account.

The Participating Member States must approve the submitted documents or deliverables as conforming to the above requirements and pay [***]. Any payment which falls due on a date which is not a business day may be made on the next succeeding business day. Any dispute by a Participating Member State of an invoice shall be provided to the Participating Contractor Affiliate in writing (along with substantiating documentation and a reasonably detailed description of the dispute) [***]. A Participating Member State will be deemed to have accepted all invoices for which the Participating Contractor Affiliate does not receive timely notification of disputes, and shall pay all undisputed amounts due under such invoices within the period set forth in this Article I.8.2. The parties shall seek to resolve all such disputes expeditiously and in good faith.

In addition to all other remedies available under this PA or at Law, if a Participating Member State fails to pay any undisputed amounts when due under this PA, the Contractor [***].

The Commission and the Participating Member States shall not, and acknowledge that they will have no right, under this PA, any Vaccine Order Form, any order, any other agreement, document or Law, to withhold, offset, recoup or debit any amounts owed (or to become due and owing) to the Participating Contractor Affiliate, against any other amount owed (or to become due and owing) to it by the Contractor or an Affiliate.[***]

I.8.3 Bank account

Payments by the Commission must be made [***]

 

I.9 Communication Details

For the purpose of this PA, communications must be sent to the following addresses:

[***]

By derogation from this Article I.9, different contact details for the Commission, the Participating Member States or the Contractor may be provided in Vaccine Order Form.

I.10 Project management

Pfizer, BioNTech and the Commission will each nominate a project manager that will be the sole contact point for and responsible for managing the overall relationship between the parties. Each Participating Member State shall in addition appoint an expert to work on PA implementation at Participating Member State level. Project meetings with the Commission and Participating Member State experts will be held regularly on a timeframe to be determined 

 

 

following execution of the PA to report, amongst other things, on progress of clinical studies, licensing activities, manufacturing status, forecast and deliveries. Details specific to each Participating Member State such as logistics and payments shall be handled directly by the respective Participating Member State experts.

I.11 Exploitation of the results of the PA

The Commission acknowledges and agrees [***] (collectively, the “Vaccine IP Rights”). [***] All rights not expressly granted by the Contractor hereunder are reserved by the Contractor.

I.12 Indemnification 

The Commission, on behalf of the Participating Member States, declares that the use of Vaccines produced under this PA will happen under epidemic conditions requiring such use, and that the administration of Vaccines will therefore be conducted under the sole responsibility of the Participating Member States. [***] 

[***]

I.13 Applicable Law and Settlement of Disputes 

This PA shall be governed by the laws of Belgium.

[***]

I.14 Other Special Conditions

The Contractor shall keep the Commission and the Participating Member States informed [***] during the pharmacovigilance or vaccine monitoring programmes in relation to the Vaccines which are the object of this PA [***].

 

 

SIGNATURES

					
	
For the Contractor,

[***]

[***]

 
	
 
	
For the Commission, on behalf and in the name of the Participating Member States,

[forename/surname/position]

	
 
	
 
	
 

	
Signature:
	
 
	
 
	
Signature:
	
 

	
Done at [place], [date]
	
 
	
Done at [place], [date]

	
In duplicate in English.
	
 
	
 

 

 

II. GENERAL CONDITIONS FOR THE FRAMEWORK CONTRACT FOR SERVICES

II.1 Definitions

All definitions are contained in Article I.2

II.2 Roles and responsibilities in the event of a joint tender

In the event of a joint tender submitted by a group of economic operators and where the group does not have legal personality or legal capacity, one member of the group is appointed as leader of the group.

II.3 Severability

Each provision of this PA is severable and distinct from the others. If a provision is or becomes illegal, invalid or unenforceable to any extent, it must be severed from the remainder of the PA. This does not affect the legality, validity or enforceability of any other provisions of the PA, which continue in full force and effect. The illegal, invalid or unenforceable provision must be replaced by a legal, valid and enforceable substitute provision which corresponds as closely as possible with the actual intent of the parties under the illegal, invalid or unenforceable provision. The replacement of such a provision must be made in good faith between the parties. The PA must be interpreted as if it had contained the substitute provision as from its entry into force.

II.4 Provision of services and supplies

	
II.4.1
	
All periods specified in the PA are calculated in calendar days, unless otherwise specified.

	
II.4.2
	
The Contractor must immediately inform the Commission of any changes in the exclusion situations as declared, according to Article 137 (1) of Regulation (EU) 2018/1046.

II.5 Communication between the parties

II.5.1 Form and means of communication

Any communication of information, notices or documents under the PA must:

	
 
	
(a)
	
be made in writing in paper or electronic format in the language of the contract;

	
 
	
(b)
	
bear the PA number and, if applicable, the Vaccine Order Form number;

	
 
	
(c)
	
be made using the relevant communication details set out in Article I.9; and

	
 
	
(d)
	
be sent by mail or email.

If a party requests written confirmation of an e-mail within a reasonable time, the other party must provide an original signed paper version of the communication as soon as possible.

 

 

The parties agree that any communication made by email has full legal effect and is admissible as evidence in judicial proceedings.

II.5.2 Date of communications by mail and email

Any communication is deemed to have been made when the receiving party receives it, unless this PA refers to the date when the communication was sent.

E-mail is deemed to have been received by the receiving party on the day of dispatch of that e-mail, provided that it is sent to the e-mail address indicated in Article I.9. The sending party must be able to prove the date of dispatch. In the event that the sending party receives a non-delivery report, it must make every effort to ensure that the other party actually receives the communication by email or mail. In such a case, the sending party is not held in breach of its obligation to send such communication within a specified deadline.

Mail sent to the Commission or the Participating Member State is deemed to have been received on the date on which the department responsible referred to in Article I.9 registers it.

Formal notifications are considered to have been received by the receiving party on the date of receipt indicated in the proof received by the sending party that the message was delivered to the specified recipient.

II.6 Liability

	
II.6.1
	
During the term of this PA, [***].

	
II.6.2
	
[***]

	
II.6.3
	
The Commission and the Participating Member States shall [***] to mitigate both (1) the damages that would otherwise be recoverable from the other or the Contractor pursuant to this PA and the Vaccine Order Forms, and (2) any costs, fees, expenses or losses that may be incurred by the Commission or the Participating Member State, or for which the Contractor may be responsible, under this PA and/or any Vaccine Order Form, by taking appropriate and reasonable actions to reduce or limit the amount of such damages, costs, fees, expenses or losses.

	
II.6.4
	
Limits on liability

	
 
	
(i)
	
Taking into account the unprecedented nature of the current COVID-19 situation and the exceptional circumstances under which the Vaccine shall be delivered, the parties explicitly agree that [***]

	
 
	
(ii)
	
[***]

	
 
	
(iii)
	
The aggregate liability of the Contractor and its Affiliates towards the Commission arising out of or relating to this PA and/or the Vaccine Order Forms (whether arising contractually or extra-contractually), shall not exceed [***]. 

 

 

	
 
	
(iv)
	
The aggregate liability of the Contractor and its Affiliates towards any of the Participating Member States arising out of or relating to this PA and/or the Vaccine Order Form concluded with that Participating Member State (whether arising contractually or extra contractually), shall not exceed [***]. 

	
 
	
(v)
	
[***]

	
II.6.5
	
No limitation of liability

	
 
	
(i)
	
Nothing in this PA excludes or limits the liability of either party for:

[***]

	
II.6.6
	
Waiver of sovereign immunity 

Each Participating Member State represents that it has adequate statutory or regulatory authority and adequate funding appropriation to undertake and completely fulfil the indemnification obligations pursuant to Article I.12 of this PA. 

	
II.6.7
	
Recall

In the event of a recall of the Vaccine [***]. 

II.7 Conflict of interest and professional conflicting interests

	
II.7.1
	
The Contractor must take all the necessary measures to prevent any situation of conflict of interest or professional conflicting interest.

	
II.7.2
	
The Contractor must notify the Commission in writing as soon as possible of any situation that could constitute a conflict of interest or a professional conflicting interest during the Implementation of the PA. The Contractor must immediately take action to rectify the situation.

The Commission may do any of the following:

	
 
	
(a)
	
verify that the Contractor’s action is appropriate;

	
 
	
(b)
	
require the Contractor to take further action within a specified deadline;

	
 
	
(c)
	
decide not to award a Vaccine Order Form to the Contractor.

	
II.7.3
	
The Contractor must pass on all the relevant obligations in writing to: 

	
 
	
(a)
	
its personnel which is directly involved in the performance of this PA;

	
 
	
(b)
	
any natural person with the power to represent it or take decisions on its behalf;

	
 
	
(c)
	
third parties involved in the Implementation of the PA, including subcontractors.

The Contractor must also ensure that the persons referred to above are not placed in a situation which could give rise to conflicts of interest.

II.8 Representations and warranties

 

 

	
II.8.1
	
Mutual representations and warranties

The parties each represent and warrant to each other the following:

	
 
	
(i)
	
Organization and authority. They have full right, power and authority to enter into this PA and to perform their respective obligations under this PA;

	
 
	
(ii)
	
No conflicts or violations. The execution and delivery of this PA by such party and the performance of such party’s obligations hereunder (i) do not conflict with or violate any laws existing as of the date of entry into force of the PA and applicable to such party and (ii) do not conflict with, violate, breach or constitute a default under, and are not prohibited or materially restricted by, any contractual obligations of such party existing as of the date of entry into force of the PA; and

	
 
	
(iii)
	
Valid execution. Such party is duly authorised to execute and deliver this PA, and the person executing this PA on behalf of such party is duly authorised to execute and bind such party to the terms set forth herein.

The above warranties shall also be given by the Participating Member States in respect of the Vaccine Orders Forms and their obligations contained therein.

	
II.8.2
	
Warranties of either party

The Contractor warrants to the Commission and the Participating Member States that: 

[***]

In the event of any breach of the Contractor’s warranties or undertakings relating to the Vaccine, the Commission’s and the Participating Member States’ [***]. 

The Commission and the Participating Member State warrant that the PA is awarded and each Vaccine Order Form is concluded in accordance with applicable Laws.

	
II.8.3
	
Anti-bribery/anti-corruption

The parties represent and warrant that, beyond the mutual consideration set forth in this PA, neither they nor their agents have provided or requested, or will provide or request, any additional incentive or benefit to or from the other party or its agents to induce either party to enter into this PA or perform any part of this PA.

The Contractor has not made, and will not make, in the performance of this PA directly or indirectly any payment, offer, promise, or authorisation of payment of money or anything of value to a government official, political party, candidate for political office, or any other person, and has not sought and will not seek improperly or corruptly to influence any government official, political party, candidate for political office, or any other person, in order to gain an improper business advantage.

	
II.8.4
	
No other warranty

Except to the extent set out expressly in this PA, all conditions, warranties or other terms which might have effect between the parties or be implied or incorporated into this PA (whether by 

 

 

statute, common law or otherwise) are hereby excluded to the fullest extent permitted by applicable Law. [***].

II.9 Confidentiality

	
II.9.1
	
Neither the Commission, a Participating Member State nor the Contractor shall, at any time, without the disclosing party’s prior written consent, disclose to any third party any of the other party’s Confidential Information.

	
II.9.2
	
The Commission, the Participating Member State and the Contractor shall:

	
 
	
(a)
	
use such Confidential Information solely for the purposes for which it was provided;

	
 
	
(b)
	
take all reasonable precautions to prevent any unauthorised use or disclosure;

	
 
	
(c)
	
not disclose or distribute any Confidential Information to any third party except as and to the extent authorised in writing to do so by the disclosing party.

	
II.9.3
	
The receiving party shall be permitted to disclose Confidential Information that is required or requested to be disclosed by a governmental authority pursuant to applicable law in connection with any other legal or administrative proceeding, provided that it (i) notifies the disclosing party of any such disclosure requirement or request as soon as practicable and (ii) furnishes only that portion of the Confidential Information which, in the opinion of the receiving party or their legal counsel, is responsive to such requirement or request and (iii) asks the court or other public body, if applicable, to treat the Confidential Information as confidential.

	
II.9.4
	
The receiving party shall disclose Confidential Information only to such of its representatives who have a need to know such Confidential Information to fulfil its obligations under this PA; provided, however, before any disclosure of Confidential Information, the receiving party shall bind its representatives receiving such Confidential Information to a written agreement of confidentiality at least as restrictive as contained in this PA; and prior to any disclosure, the receiving party shall instruct its representatives of the confidential nature of, and to maintain the confidentiality of, the Confidential Information. The receiving party shall be responsible for all actions of its representatives, including any breach of the terms hereof, regardless of whether or not such representatives remain employed or in contractual privity with the receiving party.

	
II.9.5
	
Notwithstanding the foregoing, in all cases, (a) [***], and (b) the Contractor may disclose Confidential Information to their Affiliates without prior written consent of the Participating Member States.

	
II.9.6
	
The confidentiality obligations set out in this Article II.9 are binding on the Commission, the Participating Member State and the Contractor during the Implementation of the PA and for as long as the information or documents remain confidential unless:

	
 
	
(a)
	
the disclosing party agrees to release the receiving party from the confidentiality obligation earlier;

 

 

	
 
	
(b)
	
the Confidential Information or documents become public through other means than a breach of the confidentiality obligation;

	
 
	
(c)
	
the applicable Law requires the disclosure of the Confidential Information or documents.

	
II.9.7
	
The Contractor must obtain from any natural person with the power to represent it or take decisions on its behalf, as well as from third parties involved in the Implementation of the PA a commitment that they will comply with this Article. At the request of the Commission, the Contractor must provide a document providing evidence of this commitment.

	
II.9.8
	
Neither this PA nor the performance by either party hereunder shall transfer to the receiving party any proprietary right, title, interest or claim in or to any of the disclosing party’s Confidential Information (including, but not limited to, any intellectual property rights subsisting therein) or be construed as granting a license in its Confidential Information.

	
II.9.9
	
The provisions of this Article II.9 shall survive the termination or expiration of this PA for [***], except with respect to any information that constitutes a trade secret (as defined by the applicable Law), in which case the recipient of such information will continue to be bound by its obligations under this Article II.9 for so long as such information continues to constitute a trade secret, but in no event for a period of less than [***] specified above.

	
II.9.10
	
The Contractor acknowledges that the Commission is subject to requirements laid down under Regulation (EC) 1049/2001.The Commission commits that it will consult with the Contractor on any disclosure request concerning documents containing Confidential Information as provided for in Article 4(4) of said Regulation.

II.10 Announcements and publicity

The parties shall consult together on the timing, contents and manner of any press release relating to the execution of this PA. Other than the foregoing, no party shall make, or permit any person to make, any public announcement concerning the existence, subject matter or terms of this PA or a Vaccine Order Form, the wider transactions contemplated by them, or the relationship between the parties, without the prior written consent of the other party (such consent not to be unreasonably withheld or delayed), except (i) as required by law, any governmental or regulatory authority (including, without limitation, any relevant securities exchange), any court or other authority of competent jurisdiction; or (ii) on terms that are consistent and do not go further than the matters covered in any agreed press release. For clarity, unless consent is granted pursuant to this Article II.10, no announcement or disclosure will (i) include or infer [***]. 

A party shall not use the name, trade name, service marks, trademarks, trade dress or logos of the other party in publicity releases, advertising or any other publication, without the other party’s prior written consent in each instance, provided, however, that consent is granted for public announcements pursuant to above sub-clause (ii) in this Article II.10.

II.11 Processing of personal data 

 

 

II.11.1 Processing of personal data by the Commission

Any personal data included in or relating to the PA, including its implementation, shall be processed in accordance with Regulation (EU) 2018/1725. Such data shall be processed solely for the purposes of the implementation, management and monitoring of the PA by the data controller. For the purpose of this provision, the data controller for the Commission shall be the Director-General of the European Commission's Directorate-General for Health and Food Safety. The data protection notice is available at https://ec.europa.eu/info/data-protection-public-procurement-procedures_en. 

The Contractor or any other person whose personal data is processed by the data controller in relation to this PA has specific rights as a data subject under Chapter III (Articles 14‐25) of Regulation (EU) 2018/1725, in particular the right to access, rectify or erase their personal data and the right to restrict or, where applicable, the right to object to processing or the right to data portability.

Should the Contractor or any other person whose personal data is processed in relation to this PA have any queries concerning the processing of its personal data, it shall address itself to the data controller. They may also address themselves to the Data Protection Officer of the data controller. They have the right to lodge a complaint at any time to the European Data Protection Supervisor.

II.11.2 Processing of personal data by the Contractor

The processing of personal data by the Contractor shall meet the requirements of Regulation (EU) 2016/679 and be processed solely for the purposes set out by the controller.

II.12 Subcontracting

	
II.12.1
	
The Contractor may not subcontract and have the PA implemented by third parties beyond the third parties already mentioned in its tender [***].

	
II.12.2
	
In the case of subcontracting, the Contractor remains bound by its contractual obligations and is solely responsible for the Implementation of the PA.

	
II.12.3
	
The Contractor must ensure that the subcontract does not affect the rights of the Commission and the Participating Member States under this PA.

	
II.12.4
	
[***]

II.13 Amendments

	
II.13.1
	
Any amendment to the PA or a Vaccine Order Form must be made in writing before all contractual obligations have been fulfilled. A Vaccine Order Form does not constitute an amendment to the PA.

	
II.13.2
	
No amendment can make changes to the PA or a Vaccine Order Form that might alter the initial conditions of the procurement procedure or result in unequal treatment of tenderers or contractors.

 

 

II.14 Assignment

Neither this PA nor any interest hereunder will be assignable by a party without the prior written consent of the other party, except as follows: [***] 

II.15 Force majeure

	
II.15.1
	
If a party is affected by Force majeure, it must immediately notify the other party, stating the nature of the circumstances, their likely duration and foreseeable effects.

	
II.15.2
	
A party is not liable for any delay or failure to perform its obligations under the PA or Vaccine Order Form if that delay or failure is a result of Force majeure. [***]

	
II.15.3
	
The parties must take all necessary measures to limit any damage due to Force majeure and shall use commercially reasonable efforts to avoid or minimize the delay in performance of their respective obligations affected by Force majeure.

II.16 Suspension of the implementation of the PA

II.16.1 Suspension by the Contractor

If the Contractor or a Participating Contractor Affiliate is affected by Force majeure, it may suspend the provision of the services under a Vaccine Order Form.

The Contractor or the Participating Contractor Affiliate must immediately notify the Commission of the suspension. The notification must include a description of the Force majeure and state when the Contractor or the Participating Contractor Affiliate expects to resume the provision of services.

The Contractor or the Participating Contractor Affiliate must notify the Commission as soon as it is able to resume performance of the Vaccine Order Form, unless the Commission has already terminated the PA or the Vaccine Order Form.

II.16.2 Suspension by the Commission or the Participating Member State

Pursuant to the Financial Regulation, the Commission or the Participating Member State may suspend the Implementation of the PA or performance of a Vaccine Order Form or any part of it:

	
(a)
	
if the procedure for awarding the PA or a Vaccine Order Form or the Implementation of the PA proves to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;

	
(b)
	
in order to verify whether the presumed Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations have actually occurred.

The Commission or the Participating Member State in question must formally notify the Contractor of the suspension and the reasons for it. Suspension takes effect on the date of formal notification, or at a later date if the formal notification so provides.

The Commission or the Participating Member State in question must notify the Contractor as soon as the verification is completed whether:

 

 

	
(a)
	
it is lifting the suspension; or

	
(b)
	
it intends to terminate the PA or a Vaccine Order Form under Article II.17.1, (f) or (i).

The Contractor is not entitled to compensation for suspension of any part of the PA or a Vaccine Order Form. For the avoidance of doubt, the Contractor shall not be under any obligation to deliver any Contracted Doses or the Additional Order during the suspension period, and the Delivery Schedule shall be adjusted to take into account the period of such suspension. Equally for the avoidance of doubt, the Contractor shall complete the delivery of any Contracted Doses or Additional Order that were already in transit on the date of the formal notification or at the later date indicated in the formal notification.

II.17 Termination of the PA

II.17.1 Grounds for termination by the Commission

The Commission may terminate the PA or the Participating Member State may terminate any on-going Vaccine Order Form (depending on whether the event affects the PA or the Vaccine Order Form) solely in the following circumstances:

	
(a)
	
[***] 

	
(b)
	
if the Contractor does not implement the PA or perform the Vaccine Order Form in accordance with material aspects of the PA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation; 

	
(c)
	
[***]

	
(d)
	
if the Contractor or any person that assumes unlimited liability for the debts of the Contractor is in one of the situations provided for in points (a) and (b) of Article 136(1) of the Financial Regulation4;

	
(e)
	
if the Contractor or any Related person is in one of the situations provided for in points (c) to (h) of Article 136(1) or Article 136(2) of the Financial Regulation;

	
(f)
	
if the procedure for awarding the PA or the Implementation of the PA prove to have been subject to Irregularities, Fraud (in the sense of the Financial Regulation) or breach of obligations;

	
(g)
	
if the Contractor is in a situation that does constitute a Conflict of interest or a Professional conflicting interest which would have a material adverse impact on the performance of the PA;

	
(h)
	
in case of a change regarding the exclusion situations listed in Article 136 of Regulation (EU) 2018/1046 that calls into question the decision to award the contract;

	
	 

	
4  
	
Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013, (EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing Regulation (EU, Euratom) No 966/2012, OJ L 193 of 30.7.2018, p.1 https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1544791836334&uri=CELEX:32018R1046

 

 

 

	
(i)
	
[***]

II.17.2 Grounds for termination by the Contractor

The Contractor may terminate the PA or any on-going Vaccine Order Form solely in the following circumstances:

	
(a)
	
if the Commission or the Participating Member State does not implement the PA or does not perform the Vaccine Order Form in accordance with material aspects of the PA or the Vaccine Order Form (as applicable) or is otherwise in material breach of another substantial contractual obligation, [***]

	
(b)
	
[***].

II.17.3 Procedure for termination

A party must formally notify the other party of its intention to terminate the PA or a Vaccine Order Form and the grounds for termination.

The other party [***] following the date of receipt to submit observations, including the measures it has taken or will take to continue fulfilling its contractual obligations. Failing that, the decision to terminate becomes enforceable the day after the time limit for submitting observations has elapsed in the event the grounds giving rise to termination have not been cured.

If the other party submits observations, the party intending to terminate must formally notify it. 

II.17.4 Effects of termination

Within [***] date of termination, the Contractor must submit any invoice required for services that were provided before the date of termination. 

The termination or expiration of this PA shall not affect the survival and continuing validity of Articles I.1, I.2, I.4, I.6.7, I.6.9, I.6.11, I.6.12, I.6.14, I.6.16, I.7 to I.9, I.11 to I.14, II.3, II.5, II.6, II.8.2, II.8.4, II.9 to II.11, II.15, II.17.4, II.18 to II.28, Attachment 3 (Delivery Specification) and Attachment 5 (Return and Disposal of Product Materials) or of any other provision which is expressly or by implication intended to continue in force after such termination or expiration.

Expiry or termination of this PA for any reason shall be without prejudice to either party’s other rights and remedies or to any accrued rights and liabilities as the date of such expiry or termination [***].

II.18 Invoices, value added tax and e-invoicing 

II.18.1 Invoices and value added tax

Invoices must contain the Contractor’s or the Participating Contractor Affiliate’s (or leader’s in the case of a joint tender) identification data, the amount, the currency and the date, as well as the PA reference and reference to the Vaccine Order Form.

 

 

Invoices must indicate the place of taxation of the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) for value added tax (VAT) purposes and must specify separately amounts not including VAT and amounts including VAT.

It is understood and agreed between the parties that any prices stated under this PA and Vaccine Order Form are exclusive of any VAT or similar tax and all other taxes which are incurred as a result of manufacturing and supplying the Product (including custom duties, levies and charges and all local taxes) (“Taxes”), which shall be added thereon as applicable. Where Taxes are properly chargeable on any amounts payable under this PA or Vaccine Order Form, the party making the payment will pay the amount of Taxes, as specified on the invoice, in accordance with the laws and regulations of the country in which the Taxes are chargeable. 

[***]

II.19 Payments and guarantees 

II.19.1 Date of payment

The date of payment is deemed to be the date on which [***].

II.19.2 Currency

Payments are made in euros or, for non-Eurozone countries, the local functional currency of the Participating Member State. For non-Eurozone countries, the Vaccine Order Form shall set forth the Delivery Price in the local functional currency converted from euro at the exchange rate existing one (1) day prior to the Effective Date of the PA as of 4:00pm London time published in Bloomberg FX Fixings (BFIX), such rates being found via Bloomberg or the website www.bloomberg.com/markets/currencies/fx-fixings.

 

II.19.3 Costs of transfer

The costs of the transfer are borne as follows:

	
(a)
	
the Commission or the Participating Member State in question bears the costs of dispatch charged by its bank;

	
(b)
	
the Contractor or the Participating Contractor Affiliate bears the costs of receipt charged by its bank;

	
(c)
	
the party causing repetition of the transfer bears the costs for repeated transfer.

II.19.4 Suspension of the time allowed for payment

The Commission or the Participating Member State in question may suspend the payment periods specified in Article I.8 at any time by notifying the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) that its invoice cannot be processed. [***]

Suspension takes effect on the date the Commission or the Participating Member State in question sends the notification. The remaining payment period resumes from the date on which the requested information or revised documents are received or the necessary further verification, including on-the-spot checks, is carried out. [***]

 

 

II.19.5 Interest on late payment

On expiry of the payment periods specified in Article I.8, the Contractor or the Participating Contractor Affiliate (or leader in the case of a joint tender) is entitled to interest on late payment at the higher of (a) the rate applied by the European Central Bank for its main refinancing operations in euros (the reference rate) [***] (or such centralized bank reference rate set forth in the Vaccine Order Form) and (b) [***]%. The reference rate is the rate in force, as published in the C series of the Official Journal of the European Union, on the first day of the month in which the payment period ends.

Suspension of the payment period as provided for in Article II.19.4 is not considered as giving rise to late payment.

Interest on late payment covers the period running from the day following the due date for payment up to and including the date of payment as defined in Article II.19.1.

II.20 Recovery

II.20.1 Recovery procedure

In all cases where the recovery procedure as described in the Financial Regulation applies, the parties shall follow the procedure set out in this Article.

Before recovery, the Commission or the Participating Member State in question must formally notify the Contractor of its intention to recover the amount it claims, specifying the amount due and the reasons for recovery and inviting the Contractor to make any observations [***].

If no observations have been submitted or if, despite the observations submitted, the Commission or the Participating Member State in question decides to pursue the recovery procedure, it must confirm recovery by formally notifying a debit note to the Contractor, specifying the date of payment. The Contractor must pay in accordance with the provisions specified in the debit note.

If the Contractor does not pay by the due date, the Commission or the Participating Member State in question may, after informing the Contractor in writing, recover the amounts due:

	
(a)
	
by offsetting them against any amounts owed to the Contractor by the Commission or the Participating Member State in question;

	
(b)
	
by taking legal action.

II.20.2 Interest on late payment

If the Contractor does not honour the obligation to pay the amount due by the date set by the Commission or the Participating Member State in question, the amount due bears interest at the rate indicated in Article II.19.5. Interest on late payments will cover the period starting on the day after the due date for payment and ending on the date when the Commission or the Participating Member State in question receives the full amount owed.

Any partial payment is first entered against charges and interest on late payment and then against the principal amount.

 

 

II.21 Checks and audits

	
II.21.1
	
The Commission and the European Anti-Fraud Office may check or require an audit on the Implementation of the PA. This may be carried out either by OLAF’s own staff or by any outside body authorised to do so on its behalf, provided that the auditor may not be a competitor of the Contractor.

Such checks and audits may be initiated at any moment during business hours during the provision of the services and up to [***] starting from the payment of the balance of the last specific contract issued under this PA. 

The audit procedure is initiated on the date of receipt of the relevant letter sent by the Commission. Audits are carried out on a confidential basis.

	
II.21.2
	
The Contractor must keep all original documents stored on any appropriate medium, including digitised originals if authorised under national law, for a period of [***] starting from the payment of the balance of the last specific contract issued under this PA.

	
II.21.3
	
The Contractor must grant the appropriate right of access to sites and premises where the PA is implemented, [***], needed to conduct such checks and audits. The Contractor must ensure that the information is readily available at the moment of the check or audit and, if so requested, that information is handed over in an appropriate format. The auditor must, insofar possible, comply with all applicable and reasonable security measures notified to Commission by the Contractor subject to this not creating any material obstacles for the performance of the auditor’s tasks.

	
II.21.4
	
On the basis of the findings made during the audit, a provisional report is drawn up. The Commission or its authorised representative must send it to the Contractor, who has [***]following the date of receipt to submit observations. The Contractor must receive the final report within [***] following the expiry of the deadline to submit observations.

On the basis of the final audit findings, the Participating Member State in question may recover all or part of the payments made in accordance with Article II.20 and may take any other measures which it considers necessary.

	
II.21.5
	
In accordance with Council Regulation (Euratom, EC) No 2185/96 of 11 November 1996 concerning on-the-spot checks and inspection carried out by the Commission in order to protect the European Communities’ financial interests against fraud and other irregularities and Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office, the European Anti-Fraud Office may carry out investigations, including on the spot checks and inspections, to establish whether there has been fraud, corruption or any other illegal activity under the contract affecting the financial interests of the Union. Findings arising from an investigation may lead to criminal prosecution under national law.

The investigations may be carried out at any moment during the provision of the services and up to [***] starting from the payment of the balance of the last specific contract issued under this PA.

 

 

	
II.21.6
	
The Court of Auditors and the European Public Prosecutor’s Office established by Council Regulation (EU) 2017/19398 (‘the EPPO’) have the same rights as the Commission, particularly right of access, for the purpose of checks, audits and investigations.

II.22 Relationship of the parties

The relationship hereby established between the Contractor and the Commission is solely that of independent contractors. Neither party has authority to act or make any agreements or representations on behalf of the other party. This PA is not intended to create, and shall not be construed as creating, between the parties, the relationship of principal and agent, employer and employee, joint venturers, co-partners, or any other such relationship, the existence of which is expressly denied.

II.23 Waiver

A waiver by any party of any term or condition of this PA in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach thereof. All remedies specified in this PA shall be cumulative and in addition to any other remedies provided at Law or in equity, except where expressly otherwise agreed.

II.24 Further documents

Each party hereto agrees to execute such further documents and take such further steps as may be reasonably necessary or desirable to effectuate the purposes of this PA.

II.25 Headings

Headings of Articles or other parts of this PA are included herein for convenience of reference only and shall not constitute a part of this PA or change the meaning of this PA.

II.26 Electronic Delivery and Storage

Delivery of a signed PA by reliable electronic means, including facsimile or email (with receipt electronically confirmed), shall be an effective method of delivery of the executed PA. This PA may be stored by electronic means and either an original or an electronically stored copy of this PA can be used for all purposes, including in any proceeding to enforce the rights or obligations of the parties to this PA.

II.27 Entire Agreement

This PA, together with any Annexes and Attachments, which are hereby incorporated by reference, constitute the entire agreement of the parties with respect to its subject matter and merges and supersedes all prior discussions and writings with respect to thereto. 

II.28 Costs

Each party will bear its own legal costs in preparing and concluding this PA.

 

 

Annex I: Vaccine Order Form

This Vaccine Order Form is submitted by:

 

[The Government of [•]] (the “Participating Member State”), represented for the purposes of signing this Vaccine Order Form by [forename, surname, function, department of authorising officer],

 

to:

 

Pfizer Inc, incorporated in Delaware (Registration Number 0383418) with its registered address at 235 East 42nd Street, 10017 New York City, NY (UNITED STATES) (“Pfizer”);

and

BioNTech Manufacturing GmbH, registered with the commercial register of the lower court (Amstgericht) of Mainz, Germany under HRB 47548, with its registered address at An ger Goldgrube 12, 55131 Mainz, Germany (“BioNTech”),

(Pfizer and BioNTech together the “Contractor”, represented for the purposes of signing this Vaccine Order Form by [***]).

The Participating Member State and Contractor are together referred to as the “Parties” and each individually as a “Party”.

 

WHEREAS

	
 
	
—
	
Contractor and the European Commission, acting on behalf of and in the name of the Participating Member States, entered into a Purchase Agreement for the purchase and supply of Contractor’s Vaccine for EU Member States dated [•] 2021 (the “PA”), the terms of which are binding on the Participating Member States and must be read in conjunction with this Vaccine Order Form.

	
 
	
—
	
The PA provides that each Participating Member State will submit to Contractor a Vaccine Order Form through which Contractor shall make available and deliver to the relevant Participating Member State a proportion of the Contracted Doses or Additional Order as applicable, in accordance with the allocation provided by the Commission pursuant to Article I.6.3 of the PA and at the price and conditions as set out in the PA. 

	
 
	
—
	
In accordance with Article I.5.2 of the PA, the Participating Member State hereby places its order for its full allocated portion of the Contracted Doses or Additional Order (as applicable).

 

 

Article I

Subject matter

 

	
 
	
1.
	
This Vaccine Order Form is submitted by the Participating Member State to Contractor in accordance with the terms of the PA, and forms an integral part of the PA. The terms and conditions of the PA are incorporated into this Vaccine Order Form by reference. In the event of contradiction between this Vaccine Order Form and the PA, the terms of the PA prevail regardless of any provision to the contrary. Any capitalised terms in this Vaccine Order Form will have the meaning attributed to them in the definitions list included in Article I.2 of the PA.

 

	
 
	
2.
	
This Vaccine Order Form relates to the order for the Participating Member State’s full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable) as set out in the allocation provided by the Commission to Contractor pursuant to Article I.6.2 of the PA. The submission of this signed Vaccine Order Form by the Participating Member State to Contractor constitutes a binding order by the Participating Member State for the purchase of its full allocated portion of the Contracted Doses or the relevant Additional Order (as applicable) as follows

 

	
 
	
a.
	
Participating Member State will purchase [insert amount] number of doses of [Contracted Doses] [Additional Order] of the Vaccine, on the basis of the following delivery schedule: 

	
[***]
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 

 

	
 
	
b.
	
The Delivery Price of [Contracted Doses] [Additional Order] is [***].

The total amount payable by the Participating Member State for the [Contracted Doses] [Additional Order] is [insert amount] [***].

 

	
 
	
3.
	
By signature of this Vaccine Order Form, the undersigned Participating Member State warrants to Contractor that:

 

ait is irrevocably and unconditionally bound by the terms of the PA (as concluded by the Commission on behalf and in the name of the Participating Member States), including the indemnification obligations and the liability, limitation of liability and exclusions terms set out therein;

 

bthe provisions of the PA are enforceable against it in accordance with its terms;

 

cit shall indemnify the Indemnified Persons in accordance with Article I.12 (Indemnification) of the PA;

dit has full right, power and authority to enter into this Vaccine Order Form and to perform its respective obligations under it;

 

 

ethe person executing this Vaccine Order Form is duly authorized to execute and bind the undersigned Participating Member State to the terms set forth herein and incorporated by reference.

 

	
 
	
4.
	
[***]

 

	
 
	
5.
	
The Participating Member State represents and warrants that all necessary permissions and approvals ‎have been or will be obtained prior to the time for performance by the Participating Member State, to authorise performance of all of the obligations contained herein.

 

Article II

Delivery, Supply

 

	
 
	
1.
	
Delivery Address. The Delivery Address for the Participating Member State is as follows: 

 

[• - Participating Member State to enter location of its distribution hub]

 

	
 
	
2.
	
Supply of the Products

 

The Contractor shall supply the Products as further described in the PA: [Note: Include any additional details concerning the supply here.]

 

Article III

Invoices; Notices

 

	
 
	
1.
	
Invoice and Payments. Contractor shall invoice the Participating Member State in accordance with the terms of the PA. All payments to Contractor or its designated Affiliate shall be made in accordance with the terms of the PA.

 

Payment shall be made in the following currency pursuant to the provisions of Article II.19.2: [to be completed].

 

	
 
	
2.
	
Notice. Any notice given under this Vaccine Order Form must a) be made in writing in English in paper or electronic format; b) bear the PA number and the number of this Vaccine Order Form; c) be made using the relevant communication details set out below with respect to the Participating Member State and Contractor (as applicable); d) be sent by mail and email: 

Participating Member State:

[Name of Participating Member State]

[Full official address of Participating Member State]

[Full name of addressee physical person (contact person)]

[Function of addressee physical person (contact person)]

E-mail: [complete email of addressee physical person (contact person)]

 

Contractor:

[Add details]

 

 

Article IV.

Entry into Force and Duration

 

	
 
	
1.
	
This Vaccine Order Form shall enter into force on the date of signature by the Parties and will remain into force until termination of the PA, or if the PA expires, until the last delivery of Product [***].

 

Article V.

Applicable Law and Settlement of Disputes

 

	
 
	
1.
	
For the avoidance of doubt, Article I.13 (Applicable Law and Settlement of Disputes) of the PA shall apply to any dispute arising out of the implementation of or in connection with this Vaccine Order Form and the Participating Member State irrevocably agrees to be bound by the provisions set out therein. 

 

 

(Signature page follows)

 

 

SIGNATURES

 

	
 

For the Participating Member State,

[forename/surname/position]

 

Signature:_____________________

Done at [place], [date]

	
 

 

 

For acceptance of the Vaccine Order Form,

Contractor,

[***]

Signature: _______________________

Done at [place], [date]
	
 

 

The invoice will be paid only once the Contractor has returned the signed Vaccine Order Form.

 

 

 

ANNEX II: Agreement between the Commission and Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures, annexed to the Commission Decision C(2020) 4192 final of 18 June 2020

 

Agreement

 

Preamble

 

Having regard to Article 4(5)(b) of Council regulation (EU) 2016/369 on the provision of emergency support within the Union1as amended by Council regulation (EU) 2020/521 of 14 April 2020 activating the emergency support under regulation (EU) 2016/369, and amending its provisions taking into account the COVID-19 outbreak (hereinafter “ESI” or “ESI regulation”); 

 

***

 

The European Commission (“the Commission”)

 

and

 

The following Member States: (XXX), hereinafter referred to as “the Participating Member States”

 

Together referred to as “the Parties”

 

Agree on the Following:

 

Article 1: Objective and mandate of the Commission

 

On the basis of the present agreement, the Commission is mandated to conclude, on behalf of the Participating Member States, Advance Purchase Agreements (“APA”) with vaccine manufacturers with the objective to procure vaccines for the purposes of combatting the COVID 19 pandemic at Union level.

 

The Annex to this agreement sets out the negotiating directives for this purpose.

 

Article 2: Acquisition of vaccine doses

 

It is the Participating Member States, and not the Commission, that shall acquire vaccine doses from the manufacturers on the basis of the APAs unless otherwise agreed. All relevant vaccination policies shall therefore remain matters for the Participating Member States. 

 

Article 3: APAs containing a right to acquire vaccine doses

 

Where the Commission concludes an APA in conformity with the present agreement that provides the right for the Participating Member States to acquire vaccine doses, the use of such a right shall take place by means of the conclusion of contracts between the Participating Member States and the vaccine manufacturers. There shall be no obligation for any 

 

 

Participating Member State to conclude such a contract on the basis of the APA. The APA shall contain a clause to this end. 

 

Article 4: APAs containing an obligation to acquire vaccine doses

 

Where the Commission intends to conclude, in conformity with the present agreement, an APA containing an obligation to acquire vaccine doses, it shall inform the Participating Member States of such intention and the detailed terms. In case a Participating Member State does not agree with the conclusion of an APA containing an obligation to acquire vaccine doses or its terms, it has the right to opt out by explicit notification to the Commission within 5 working days after the Commission has communicated its intention to conclude the APA. All Participating Member States not having opted out within the period of 5 working days are deemed to have authorised the Commission to negotiate and conclude the APA with the vaccine manufacturer in their name and on their behalf. 

 

Article 5: The legally binding nature of APAs

 

Once concluded, the terms of the APA shall be legally binding on the Participating Member States, except for those who have exercised their right to opt out.

 

Article 6: Responsibility and liability

 

The present Agreement regulates only the division of potential liability and indemnification between the Commission and the Participating Member States. It does not regulate the extent to or the conditions under which potential liability of the vaccine manufacturer may be taken over or indemnified under the APAs. 

 

The Commission shall be exclusively responsible for the procurement process and the conclusion of APAs including any liability arising out of the conduct of the negotiations. 

 

Participating Member States acquiring a vaccine shall be responsible for the deployment and use of the vaccines under their national vaccination strategies, and shall bear any liability associated with such use and deployment. This shall extend to and include any indemnification of vaccine manufacturers under the terms and conditions of the relevant APA for liability related to the use and deployment of vaccines normally borne by such manufacturer.

 

Article 7: Obligation not to negotiate separately

 

By signing the present Agreement, the Participating Member States confirm their participation in the procedure and agree not to launch their own procedures for advance purchase of that vaccine with the same manufacturers.

 

In case an APA containing an obligation to acquire vaccine doses has been concluded with a specific manufacturer, the Member States having made use of the opt-out provided under the present Agreement can enter into separate negotiations with the same manufacturer after the APA under the present Agreement has been signed.

 

 

 

Annex

 

Initial considerations

 

A permanent solution to the COVID-19 crisis is most likely to be brought about by the development and deployment of a safe and effective vaccine against the virus. Every month gained in the deployment of a vaccine will save many lives, many jobs and billions of euros.

 

Therefore, it is the objective of the present Agreement that the EU takes steps to secure sufficient supplies of a safe and effective vaccine for Member States. 

 

Structure and purpose of the procurement

 

Work on a COVID-19 vaccine is challenging for many reasons: the shortened development timeframe, the large upfront costs for manufacturers, the high failure rate during clinical trials. If vaccine producers follow their usual practice of making investments in production capacity only when they are sure of a viable product, this will result in considerably longer waiting times for a vaccine. Investments need to be made now in order to ensure that vaccines are being produced at the scale required as early as possible.

 

Under the present agreement, this challenge will be addressed through concluding EU-level Advance Purchase Agreements (“APA”) with vaccine manufacturers when necessary, to secure access to vaccine candidates where they are successful, including up-front EU financing to de-risk essential investments to increase the speed and scale of manufacturing successful vaccines. Funding for the up-front payments will come from the Emergency Support Instrument (ESI).

 

The Parties understand that developing a safe and effective vaccine is a highly complex process and the risk of failure in any such venture is very high. Therefore, the aim is to put in place APAs with a number of manufacturers of leading vaccine candidates, to maximise the chances of having access to at least one successful vaccine.

 

The Commission will invite all vaccine manufacturers to manifest interest. In general, the Commission will give priority to negotiating specific APAs with those manufacturers that (a) have entered or have firm plans to enter clinical trials still in 2020, (b) have the capacity to develop a successful vaccine and (c) have a proven capacity to produce at scale already in 2021. 

 

Process and governance

 

In order to run the procurement centrally and efficiently, the European Commission will set up a steering board for the process subject to Article 6 of the present Agreement. It will be co-chaired by the European Commission and a Participating Member State with experience in the negotiations and production capacities for vaccines. The steering board will include senior officials from all Participating Member States to assist and provide guidance throughout the evaluation process. 

 

The co-chairs of the steering board will propose a team of a limited number of experts with relevant experience for the ongoing negotiations from six Participating Member States with production capacities for vaccines. These experts will join with the European Commission in a negotiation team (“joint negotiation team”), which will work on a continuous basis as one 

 

 

unit. That joint negotiation team will start work immediately building on previous contacts with individual companies by the European Commission and Participating Member States. In order to launch negotiations with a specific manufacturer, there needs to be support from at least four Participating Member States. The joint negotiation team will make its best effort to take the advice of the steering board into account in the negotiations and will report back to the steering board on a regular basis on the progress made in negotiating with individual companies. 

 

For compliance with the applicable rules, all members of the steering board and the joint negotiation team will obtain the status of experts associated to the procurement process as provided in the Financial Regulation. Given their access to highly sensitive business information, all those members will be required to sign strict confidentiality and no-conflict-of-interest agreements.

 

Assisted by the steering board, the European Commission will then decide which of the resulting APAs should be concluded, in particular if financing under ESI is insufficient to finance all relevant packages. The Commission will only consider those APAs for financing where at least four Participation Member States have expressed agreement. Before making any final decisions, the Commission will seek independent scientific advice on the state of progress and the available data on quality, safety and efficacy for the vaccine candidate in question. 

 

Should financing under ESI be insufficient, Participating Member States can decide to top up ESI funding to make up the gap to finance all packages. In such a case where there are opportunities to conclude further APAs but money from ESI is no longer sufficient, Participating Member States will have the opportunity to express their interest in such opportunities. If at least four Participating Member States express interest, those Participating Member States will make use of the possibility of a voluntary contribution to ESI to the required amount allowing the Commission to proceed with signing the APA only on behalf of those Member States that have expressed interest and contributed the funds to ESI.

 

For full transparency, the European Commission will report to the IPCR at least once every two weeks on overall progress more generally.

 

Advanced Purchase Agreements and conditions

 

To conclude APAs, the joint negotiating team will negotiate funding packages with individual vaccine producers in return for the right to buy a specific number of vaccine doses in a given timeframe and at a certain price. 

 

As outlined in the present Agreement, the European Commission also has the possibility to conclude APAs including an obligation to procure the vaccine if it becomes available, where the conditions (notably the pricing) of those APAs make this worthwhile and in line with the conditions in the present Agreement. If in such a case the distinction between upfront payments and purchase price is difficult to draw, the Commission will share the total cost related to the vaccine purchase but will in any case contribute no more than 50% of the total cost. 

 

Funding provided up front will be considered as an advance payment for any eventual purchase by Member States, thus reducing the amount that Member States will have to pay when eventually purchasing that vaccine. 

 

 

 

The up-front payments under the APAs shall be used by manufacturers to de-risk the necessary investments related to both vaccine development and clinical trials, and the preparation of the at-scale production capacity along the entire vaccine production value chain in the EU required for a rapid deployment of millions of doses of an eventual vaccine. The relevant payments should be structured according to the need of the manufacturer, but subject to the state of the vaccine development, in particular relying on transparency of the associated clinical data and its assessment, at the time of payment. This is in order to avoid obligations to pay in situations where the development work has shown a vaccine candidate likely to be unsuccessful.

 

The purchase price of the vaccine, as well as the amount of funding provided up front will take into account a transparent estimation of production costs (supported by independent audits where available), as well as the resources already granted from other public sources. Under the APA, the manufacturer can be asked to provide ex post proof supported by independent audits concerning the activities financed by these payments. 

 

The aim of the negotiation is to conclude APAs with individual companies under the best possible conditions. These APAs should specify details with respect to: 

 

	
 
	
a)
	
Payments to be made, such as payment amounts, payment schedules, type of payments requested and the use of those payments related to de-risk investment, financing clinical trials, providing working capital and scaling-up production capacity;

	
 
	
b)
	
Delivery details of the vaccine if successful, such as price per person immunised (or alternatively, number of doses required per person immunised and price per dose), quantity of doses to be delivered and delivery timeline following approval; 

 

and

 

	
 
	
c)
	
Any other relevant conditions, such as production capacity built or used in the EU or liability arrangements. 

 

For liability arrangements, the joint negotiation team will make its best effort to limit what is required by individual companies for the purpose of indemnification to be included in the terms and conditions of the APA.

 

The APAs will contain provisions to clarify the law applicable to both the APA and resulting purchase orders as well as the competent courts. The Participating Member States agree that each APA negotiated by the Commission on their behalf with a vaccine manufacturer will have the same applicable law for all Participating Member States, and that the courts corresponding to that applicable law will be competent to hear disputes arising from that APA.

 

When taking a decision to finance individual APAs, the European Commission, in consultation with the steering board, will take into account the following elements: any available data on quality, safety and efficacy of the vaccine at time of negotiation of the contract, speed of delivery at scale, cost, risk-sharing, diversification of technologies, capacity to supply through development of production capacity within the EU, possible flexible future use of any capacity funded, engagement at an early stage with EU regulators with the intention to apply for an EU marketing authorisation for the candidate vaccine(s), commitment to supply vulnerable countries. 

 

 

 

The procedure outlined above complies with the ESI Regulation and the Financial Regulation. The latter is aligned to the European procurement Directives, which also provide the basis for national procurement rules. Participating Member States may rely on the procedure run by the European Commission to directly purchase vaccines from the manufacturers as and when any of the vaccines becomes available based on the conditions laid down in the APA. Access to vaccine doses will be allocated to Participating Member States according to the population distribution key.

 

In the negotiations with the pharmaceutical industry under the present Agreement, the Commission will promote a Covid-19 vaccine as a global public good. This promotion will include access for low and middle income countries to these vaccines in sufficient quantity and at low prices. The Commission will seek to promote related questions with the pharmaceutical industry regarding intellectual property sharing, especially when such IP has been developed with public support, in order to these objectives. Any vaccines available for purchase under the APAs concluded but not needed and purchased by Participating Member States can be made available to the global solidarity effort.

 

 

Annex III: Participating Member States

Germany

France

Italy

Spain

Austria

Greece

Cyprus

Malta

Denmark

Sweden

Finland

Ireland

Portugal

Belgium

Luxembourg

Netherlands

Poland

Romania

Bulgaria

Slovenia

Croatia

Czech Republic

Hungary

Slovakia

Lithuania

Latvia

Estonia

 

 

Annex IV: SUBCONTRACTORS

 

[***]

 

 

Annex V – PARTICIPATING CONTRACTOR AFFILIATES

 

	
Country
	
Participating Contractor Affiliate

	
Germany
	
BioNTech Europe GmbH

	
France
	
Pfizer SAS

	
Italy
	
Pfizer S.r.l.

	
Spain
	
Pfizer S.L.U.

	
Austria
	
Pfizer Corporation Austria GmbH

	
Greece
	
Pfizer Hellas SA

	
Cyprus
	
Pfizer Hellas SA

	
Malta
	
Pfizer Hellas SA

	
Denmark
	
Pfizer ApS

	
Sweden
	
Pfizer Innovations AB

	
Finland
	
Pfizer Finland Oy

	
Ireland
	
Pfizer Healthcare Ireland

	
Portugal
	
Pfizer Biofarmacêutica Sociedade Unipessoal, Lda

	
Belgium
	
Pfizer SA

	
Luxembourg
	
Pfizer Luxembourg S.A.R.L.

	
Netherlands
	
Pfizer BV

	
Poland
	
Pfizer Trading Polska sp. z o.o.

	
Romania
	
Pfizer Romania SRL

	
Bulgaria
	
Pfizer Export B.V.

	
Slovenia
	
Pfizer Export B.V.

	
Croatia
	
Pfizer Export B.V.

	
Czech Republic
	
Pfizer PFE, spol. s r.o.

After 1/12 shall be merged into Pfizer, spol. s r.o.

	
Hungary
	
Pfizer Gyógyszerkereskedelmi Kft.

	
Slovakia
	
Pfizer Export B.V.

	
Lithuania
	
Pfizer Export B.V.

	
Latvia
	
Pfizer Export B.V.

	
Estonia
	
Pfizer Export B.V.

 

In addition, any Contractor Affiliate which is involved in the sale or distribution of Product which is resold or donated by a Participating Member State shall be deemed to be a Participating Contractor Affiliate.

 

 

Attachment 1: SPECIFICATIONS

 

[***]

 

 

Attachment 2: Delivery Documentation

 

 

[***]

 

 

Attachment 3: Delivery Specification

 

 

[***]

 

 

 

Attachment 4: Labelling and Packaging Specifications

 

 

[***]

 

 

 

Attachment 5: Return and Disposal of Product Materials

 

 

[***]bntx-ex453_417.htm

 

Exhibit 4.53

 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN

IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM

THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND

(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE

COMPANY IF PUBLICLY DISCLOSED

Lease

 

concerning

 

Areas and Spaces in Buildings H028 and H030

(Buildings H028 and H30 are hereinafter jointly

referred to as “Building H028”)

 

at the Behringwerke Site in Marburg

 

between

 

Pharmaserv GmbH

Emil-von-Behring-Strasse 76, 35041 Marburg

 

- hereinafter referred to as the “Lessor” –

 

and

Novartis Manufacturing GmbH

Emil-von-Behring-Strasse 76, 35041 Marburg

 

- hereinafter referred to as the “Lessee” –

 

The Lessor and Lessee are also referred to individually as a “Party” or

jointly as the “Parties”

 

 

Preamble

 

[***]

 

 

 

 

 

Section 1

Leased Object

 

	
(1)
	
The Lessor, in its capacity as the owner, leases to the Lessee the areas and spaces marked in green within the Buildings H028 and H030 (Buildings H028 and H30 will be hereinafter also referred to jointly as “Building H028”) shown in Annex 1.4) (“Site Plan”), at the Behringwerke Site, Emil-von-Behring-Strasse 76, 35041 Marburg, including the traffic areas and ancillary areas, to the extent that these traffic areas and ancillary areas are marked in “green” instead of “grey” in Annex 1.1) (hereinafter jointly referred to as the “Leased Object”).

 

	
(2)
	
The areas and spaces marked in green in Annex 1.2) (hereinafter referred to as the “Additional Areas”) will be included in the Lease as from 01.01.2025. However, by way of deviation from the previous sentence, the Additional Areas will be included in the Lease as early as 01.01.2024 if the Lessor informs the Lessee in writing of the earlier lease start date by no later than 31.12.2022.

 

From the date of inclusion of the Additional Areas in the Lease, the Leased Object will comprise the areas and spaces as shown in Annex 1.3) to this Lease.

 

	
(3)
	
The technical areas marked in blue may be jointly used by the Lessee free of charge for the installation of the Lessee’s own technical equipment, depending on the space available. 

 

The external roof areas, façade surfaces and external parts of the building are not included in the Lease. The Lessee is permitted to use these roof areas and façade surfaces free of charge in agreement with the Lessor only if they are required in order to fulfil the purpose of the Lease as set out in Section 2 of this Lease.

 

Components of the Leased Object include its building construction, facilities and installations, only insofar as and to the extent that these are listed in Annex 2.1), Annex 2.2) (Additional Areas) and Annex 2.3).

 

If the building construction, facilities and installations are not listed in Annex 2.1), Annex 2.2) (Additional Areas) and Annex 2.3), they do not form part of the Leased Object.

More specifically, the Lease does not cover the extension to the Leased Object for pharmaceutical purposes (building construction, facilities and installations) carried out in the Leased Object by the Lessee and the previous lessees, [***].

 

The Lease also does not cover – and it is therefore not listed as leased in Annex 2.1), Annex 2.2) and Annex 2.3) – the necessary infrastructure for energy and media transmission, such as supply lines, from the output terminal of the main distributor, and from the first shut-off valve in the central energy room. This infrastructure is in the possession of [***], and the Lessee will agree with [***] on the usage and transfer of this infrastructure outside the scope of this Lease.

 

	
(4)
	
The Lessee is permitted sole use of the area for storing waste containers allocated to Building H028 as per Annex 1.4) and listed as such therein, on the eastern side of Talstrasse, to the north of Building H028, and joint use of the area to the south of Building H028 with the other users of Building H028, free of charge and in accordance with all applicable legal provisions, more specifically to an extent that corresponds to the proportion of the Leased Object surface area provided to the Lessee in m2  in relation to the surface area of all leasable areas in Building H028.

Page 2 of 20

 

 

	
(5)
	
The description of the Leased Object in this Lease merely constitutes an agreement on quality rather than a guaranteed characteristic.

 

	
(6)
	
The Lessor is authorised to have the technical equipment available in the Leased Object, in particular fire alarms and fault indication systems, including the infrastructure necessary for these, and to install, reposition, dismantle, extend, operate, and renew them. The Lessor is authorised to enter the Leased Object at any time for this purpose in agreement with the Lessee or arrange for it to be entered by appointed third parties. In the event of imminent danger, entry is authorised even without agreement; however, the Lessor must notify the Lessee after it has carried out the work.

Page 3 of 20

 

Section 2

Purpose of the Lease, Value Added Tax,

Orders, Requirements, Approvals

 

	
(1) 
	
The Lessor provides the Lessee with the Leased Object for the purpose of carrying out pharmaceutical activities, using its own expansions and the Lessor’s expansions, which the Lessee purchases directly from the previous lessee independent of this Lease. The areas leased in Building H030 are leased only for the storage of the goods described in more detail in Annex 8) to this Lease.

 

	
(2) 
	
If special installations, fittings (for example floor coverings or air conditioning units) or structural amendments beyond those set out in Annex 2.1), Annex 2.2) (Additional Areas) and Annex 2.3) are required for a special use within the scope of the agreed purpose of the Lease, it is the responsibility of the Lessee to arrange for these within the framework of the existing building permit, at its own risk and expense, and to obtain any necessary further approvals. In the event of termination of the Lease, Section 14 of this Lease will apply.

 

The Lessor approves these installations, fittings or structural amendments within the framework of the existing building consent. However, the Lessor assumes no liability for the suitability of the provided rooms and areas for a renovation and for special use by the Lessee, and more specifically it assumes no liability for compliance with the public-law provisions applicable to the operation envisaged by the Lessee, the accident prevention regulations, the VDS [German corporate security and safety] and TÜV [German technical inspection association] guidelines and the availability of the supply, disposal and sanitary facilities required for use by the Lessee. It is up to the Lessee alone, at its own expense and risk and under its own responsibility, to provide all necessary conditions, and in particular comply with the public laws (e.g. building consent) and technical and structural requirements for the amendments to the Leased Object in the areas and spaces provided, made by the previous lessees and the Lessee and any amendment to be made by it in the future, and for the usage envisaged by the Lessee, and to meet the requirements imposed by authorities at its own expense. If installations, fittings or structural amendments require an adjustment to the building consent, these require the consent of the Lessor, which will only refuse this if there is an important reason to do so.

	
(3)
	
The Lessee commits to putting in place and maintaining the required fire protection in the Leased Object with respect to the extension already carried out or to be carried out in the future by it or by third parties, at its own expense. This also applies accordingly to all future amendments to be made in the Leased Object by the Lessee itself.

 

	
(4)
	
The Lease is for business purposes within the meaning of the German Value Added Tax Act.

 

The Lessee declares that it and any future sublessees will use the Leased Object exclusively for revenues that do not preclude input tax deduction by the Lessor (Sections 9 (2) of the German Value Added Tax Act, 27 (2) of the German Value Added Tax Act). Where requested to do so by the Lessor, the Lessee will provide it with suitable evidence of the fact that it and any future sublessees are using or have used the Leased Object exclusively for revenue that does not preclude input tax deduction by the Lessor. The Lessee warrants that it will impose on any future sublessees the obligation to use the Leased Object exclusively for revenues that do not preclude input tax deduction by the Lessor.

 

If the Lessee or any future sublessees generate revenues in the Leased Object that preclude input tax deduction by the Lessor contrary to the above provision, it must notify the Lessor of 

Page 4 of 20

 

this immediately. In this case, it is obliged to compensate the Lessor for any proven disadvantage suffered by it as a result of the lost input tax deduction. The Lessee is obliged to produce any relevant evidence requested by the Tax Authority.

 

	
(5)
	
A change of use in accordance with paragraph (1) above requires the prior written consent of the Lessor, to which the Lessee has no entitlement.

 

	
(6)
	
Official orders and requirements and necessary approvals which are exclusively based on or required due to the general quality and/or location of the Leased Object must be fulfilled or obtained by the Lessor at its own expense, for the entire term of the Lease.

 

If official requirements and/or the obtaining/retention of official permits results from the Lessee’s personal or special operational circumstances or from the special circumstances of its commercial operations, the Lessee will be solely responsible for the related measures and costs.

 

To this extent, the Lessee must also fulfil any official orders and requirements issued in relation to the Leased Object during the term of the Lease at its own expense, even if they are directed at the Lessor. The Lessor will provide the Lessee with the necessary and reasonable support in this regard.

 

Section 3

Term of the Lease

 

(1)The Lease begins

- on 01.07.2019 for the areas described in more detail in Annex 1.1).

- for the Additional Areas, in accordance with the provision laid down in Section 1 (2) of the Lease. The date from which the Additional Areas will also be included in the Lease will be agreed by the Parties in an amendment to this Lease which complies with the written form requirement.

 

For all areas as a single unit, the Lease will end on 31.12.2034 (“Fixed Lease Term”) without any Party being required to give notice to terminate.

 

	
(2)
	
The Lessee has the right by unilateral declaration to extend the term of this Lease after expiry of the Fixed Lease Term for a period of five years on three consecutive occasions (“Option Right”) and the provisions of the Lease will continue to apply. The extension of the Fixed Lease Term by five years in each case will be hereinafter referred to as the “Extended Period”. The adjustment of the rent excluding utilities during the Extended Periods is provided for in Section 6 of this Lease. The Lessee must declare in writing to the Lessor that it is exercising its Option Right no later than 12 months before expiry of the Fixed Lease Term, and otherwise no later than 12 months before the end of an Extended Period. The date of receipt of the declaration by the Lessor will be the decisive date.

 

(3)Tacit extension of the Lease pursuant to Section 545 of the German Civil Code is excluded.

 

Page 5 of 20

 

Section 4

Uninterrupted Possession of the Leased Object, Handover of Additional Areas, Contractual Compliance

 

	
(1)
	
As regards the areas described in more detail in Annex 1.1), the Lessee is already in possession of the Leased Object. The Parties confirm that the Lessee’s possession will be maintained without interruption.

 

	
(2)
	
As regards the Additional Areas described in more detail in Annex 1.2), the Parties agree that these areas will be handed over to the Lessee by the Lessor in accordance with the start of the Lease, either on 01.01.2024 or 01.01.2025.

 

	
(3)
	
The Lessee acknowledges that the Leased Object is suitable for the purpose of the Lease.

 

Section 5

Rent

 

	
(1)
	
The monthly net rent excluding utilities (graduated rent) owed by the Lessee is the net rent excluding utilities agreed in Annex 4.1) until the inclusion of the Additional Areas in the Lease.

 

	
(2)
	
As soon as the Additional Areas are included in the Lease pursuant to Section 1 (2), the Lessee will owe the net rent excluding utilities for all leased areas depending on the Additional Areas are included in the Lease, as agreed in Annex 4.2) (from 01.01.2024) or Annex 4.3) (from 01.01.2025).

 

If the Lease is extended beyond the end of the Fixed Lease Term by the exercise of the Option Right pursuant to Section 3 (2) of this Lease, the monthly rent excluding utilities will be adjusted pursuant to the provisions in Section 6 of this Lease.

 

	
(3)
	
With respect to the net rent excluding utilities and with respect to all operating costs pursuant to Section 7, the Lessee additionally pays value added tax at the valid rate during the performance period, i.e. currently 19%.

 

	
(4)
	
The monthly net rent excluding utilities, including the advance payment for operating costs pursuant to Section 7, must be paid to the Lessor, without charges and in advance, by the third working day of the relevant month at the latest, into the account at [***].

 

	
(5)
	
The Lessee may only set off claims against the Lessor’s payment and exercise a right of retention only if it has recognised or legally determined counterclaims. 

Section 6

Rent Adjustment if Option is Exercised

 

Only in the event that the Lease is extended beyond 31.12.2034 (“Fixed Lease Term”) by the exercise of the option (Section 3 (2)), the following applies to the adjustment of the rent excluding utilities from 01.01.2035 onwards:

 

	
(1)
	
Starting on 01.01.2035, the minimum monthly rent will be adjusted automatically on 1 January of each year on a percentage basis, in accordance with the change to the Consumer Price Index for Germany (2010=100). The first adjustment will take place on 01.01.2035 based 

Page 6 of 20

 

		
on the change in the index for the month of December 2034 compared with the month of December 2033. The following adjustments will take place accordingly with effect from 1 January, in accordance with the change in the index for the December of the previous year compared with the December of the year preceding the previous year.

 

	
(2)
	
If the Consumer Price Index determined by the Official Statistics Office for the Federal Republic of Germany is discontinued, not replaced by another index or changed to another benchmark index, the amended index will replace the index referred to in paragraph (1). Moreover, the Parties mutually undertake to agree a corresponding provision that comes closest in economic terms to the provisions agreed herein.

 

	
(3)
	
In the event of a change to the index, which leads to an adjustment of the rent pursuant to paragraph (1), the Lessor will notify the Lessee of this immediately in writing, without the notification and obligation for the Lessee to pay the adjusted rent being a prerequisite for payment. However, until the notification, no late payment interest will be owed by the Lessee or Lessor. A failure to notify or a delayed notification does not entail a waiver of the right to adjust the rent.

 

	
(4)
	
The Parties jointly assume that pursuant to Section 3 (1) of the German Price Clause Act of 7 September 2007, the indexation clause agreed in this Lease is admissible and no Party within the meaning of Section 2 (1) of the German Price Clause Act is inappropriately disadvantaged.

 

	
(5)
	
If Section 3 (1) of the German Price Clause Act is inapplicable and/or the indexation clause is inadmissible, the Parties undertake to agree an admissible provision that comes closest in economic terms to the indexation clause agreed in this Lease.

 

Section 7

Operating Costs

 

	
(1)
	
As a general rule, the Lessee bears all operating costs in addition to the net rent excluding utilities. Operating costs are costs charged to the Lessor on an ongoing basis as a result of its ownership of the property or the intended use of the Leased Object, the building (comprising Building H028 North, Building H028 South and Building H030), its facilities and installations, and the property. The operating costs to be borne by the Lessee include the operating costs pursuant to Annex 5.1) to this Lease, provided that the Lessee has not rented the Additional Areas. From the date of inclusion of the Additional Areas, Annex 5.1) will apply instead of Annex 5.2), since from this date, the Lessee will no longer be supplied with energy and media in Building H028 South by the Lessor within the framework of this Lease, and the Lessee will enter into separate energy and media supply contracts in order also to supply Building H028 South and/or include the delivery point H028 South in any existing energy and media supply contracts. The operating costs to be borne by the Lessee also include the operating costs labelled as “Basic Infrastructure Costs” and “Drainage Costs” in Annex 5.1) and Annex 5.2), charged to the Lessor on an ongoing basis as a result of the operation of the Behringwerke Site.

 

	
(2)
	
If public taxes are newly introduced or if the Lessor is charged new operating costs within the meaning of this Lease by fulfilling legal obligations in relation to the Leased Object arising after conclusion of the Lease, these may be allocated pursuant to this Lease and a corresponding adjustment made to the advance payment for operating costs. The adjustment of operating costs referred to in Annex 5.1) and Annex 5.2) and the creation of new operating costs, which concern neither public taxes nor the fulfilment of legal obligations in relation to 

Page 7 of 20

 

		
the Leased Object arising after conclusion of the Lease, may only take place while taking the principle of sound financial management into account. The Lessor will inform the Lessee immediately of any adjustments to operating costs.

 

	
(3)
	
If the Lessor provides services within its own business operations which, if performed by third parties, would be charged as part of the operating costs pursuant to this Lease, the Lessor may issue a cost estimate for these services in an amount which corresponds to appropriate consideration, plus the value added tax applicable to these services during the period of performance insofar as applicable (e.g., where agreed, supply of energy and media at the prices applicable to the site, lift maintenance)

 

	
(4)
	
Unless precluded by mandatory provisions, the operating costs will be allocated according to the proportion of surface area held by the Lessee in relation to the total surface area of the building. The ratio between the Lessee’s proportion of surface area and the total surface area of Building H028 before inclusion of the Additional Areas, agreed only for the purpose of allocating the operating costs, is agreed by the Parties with binding force in Annex 3.1) to this Lease. The ratio between the Lessee’s proportion of surface area and the total surface area of Building H028 after inclusion of the Additional Areas, agreed only for the purpose of allocating the operating costs, is agreed by the Parties with binding force in Annex 3.2) to this Lease. 

 

	
(5)
	
The areas described in more detail in Annex 1.1) and located in Building H028 North are supplied with energy and media not within the framework of this Lease, but instead on the basis of the supply contracts to be entered into by the Lessee outside of this Lease.

 

The areas described in more detail in Annex 1.1) and located in Building H028 South are supplied with energy and media within the framework of this Lease only until the inclusion of the Additional Areas in the Lease. From the time of inclusion of the 

 

Additional Areas, the Lessor’s obligation under this Lease to supply the Lessee with energy and media in Building H028 South will end.

 

The Parties agree that the supply limit/transfer point for all energy and media supplied is the outlet of the relevant shut-off devices and/or output terminals of the Lessor’s main distributor in the central energy room. The distribution/onward transfer of energy and media in Building H028 South to the areas rented by the Lessee will be agreed between the Lessee and [***] outside of this Lease.

 

Until the time of inclusion of the Additional Areas in the Lease, the costs for supplying H028 South with energy and media will be billed based on consumption, as follows:

 

For each type of energy and media, an assessment of the total energy and media quantities supplied to Building H028 South will be drawn up based on information from the Lessor’s metering points.

 

[***]

 

[***]

 

According to the Lessee’s share in the relevant energy and media consumption determined in this manner, the supply costs will be allocated within the framework of the operating costs billing.

Page 8 of 20

 

 

As soon as H028 South is fully rented by the Lessee, the following applies:

 

For each type of energy and media, an assessment for the total energy and media quantities supplied to Building H028 will be drawn up based on information from the Lessor’s metering points. The Lessee will enter into energy and media supply contracts with the Lessor or third parties in order to supply the Leased Object, if this has not been done already. If and to the extent that energy and media supply agreements are already in place between the Lessor and Lessee, these may be extended to include the delivery points in Building H028 South.

 

	
(6)
	
For the future, the Lessor may change the allocation criteria at its discretion in agreement with the Lessee. 

 

	
(7)
	
The operating costs labelled as “Basic Infrastructure Costs” and “Drainage Costs” in Annex 5.1)/Annex 5.2) will be determined for the billing year pursuant to the agreement set out in Annex 5.1)/Annex 5.2), and allocated to the Lessee in accordance with the arrangements described and agreed in Annex 5.1)/Annex 5.2). The Basic Infrastructure Costs and Drainage Costs are not subject to the monthly advance payment for operating costs (Annex 5.3)); instead, they are billed for separately by the Lessor and reimbursed by the Lessee. 

 

	
(8)
	
If there are fire alarms and fault indication systems or any other technical fittings required for the operation of the building – except for access control installations – located in areas used jointly with other lessees of Building H028, the costs of these installations will be borne by the Lessee in proportion to the spaces used exclusively by it compared with the total surface area of Building H028 (Annexes 3.1 and 3.2)). The same applies to lightning protection.

 

	
(9)
	
The Lessee will pay monthly advance payments for operating costs, which will be determined as follows if they are not those operating costs labelled as “Basic Infrastructure Costs” and “Drainage Costs”:

 

For each calendar year, the Lessor will estimate a planned amount of the operating costs, adjusted to account for the operating costs actually incurred for the previous year, and invoice the Lessee on a monthly basis for 1/12 of this amount, plus value added tax, as an advance payment for the operating costs.

 

	
(10)
	
Energy and media consumption will be invoiced for on a monthly basis. No advance payment has been agreed.

 

	
(11)
	
After expiry of the billing period (calendar year), when invoicing for operating costs, the Lessor will determine all operating costs incurred during the billing period. The Lessor will compare the operating costs actually incurred with the advance payment for operating costs paid by the Lessee and will notify the Lessee of the result when invoicing for the operating costs.

 

	
(12)
	
Any difference between the amount of the advance payment and the amount of the invoice in the Lessor/Lessee’s favour must be settled by the Lessor/Lessee within three (3) months after receipt of the invoice by the Lessee, plus the value added tax applicable at the time of payment.

 

	
(13)
	
The Lessee must notify any objections to an invoice in writing to the Lessor within three (3) months after receipt of the invoice; otherwise, any objections to the accuracy of the invoice will be excluded unless (i) the Lessee is not responsible for the delay in asserting the 

Page 9 of 20

 

		
objections, or (ii) the Lessor did not specifically refer to the cut-off point and the consequences of its expiry in the invoice letter.

 

At the Lessee’s request, the Lessor will grant the Lessee access to the invoicing documents in the Lessor’s business premises during usual business hours, by prior appointment within four weeks after receipt of the invoice.

 

	
(14)
	
If the Lessee moves out during the invoicing period, in the event of doubt, the apportionment for the next invoice due will take place in proportion to the leasing period compared with the invoicing period.

 

	
(15)
	
The current advance payment amounts as at the start date of the Lease are appended to this Lease as Annex 5.3). The Parties agree that in the event of an amendment to the advance payment amounts, Annex 5.3) will not be adjusted and no new annex to the Lease will be created; instead, a simple notification of the amendment (e.g. in the form of a bill) by the Lessor will be sufficient.

 

	
(16)
	
The Lessor must provide the Lessee with the invoice no later than by the end of the 12th (twelfth) month after the end of the invoicing period. After expiry of this period, any subsequent claim by the Lessor is excluded, unless the Lessor is not responsible for the delay in asserting such claim.

 

Section 8

Operator Liability

	
(1)
	
The Lessee must create and maintain all the conditions required to operate its business at its own expense (operator liability).

 

Requirements of the trade inspectorate or other authorities must be fulfilled by the Lessee at its own expense, to the extent that corresponding requirements are specifically associated with the business of the Lessee or its activities in the Leased Object, even if they are directed at the Lessor. Section 2 (6) of this Lease is not affected by this.

 

The Lessee will conduct its business in the Leased Object in accordance with applicable laws and in accordance with the requirements of national and international authorities.

 

	
(2)
	
The Lessee shall hold the Lessor harmless against all claims asserted against the Lessor by third parties as a result of a breach of the operator liability requirements that apply to the Lessee.

Page 10 of 20

 

Section 9

Warranties, Liability

 

	
(1)
	
The Lessee is aware that the Leased Object is located on an industrial site, and that annoyances typical of industrial sites may be caused during the term of the Lease, such as emissions from neighbouring users, works on supply lines, roads, neighbouring buildings and plots.

 

	
(2)
	
The strict liability of the Lessor to compensate for initial defects is excluded.

 

The exclusion of liability for initial defects also applies to rights and entitlements in relation to rectification of defects, deterioration, termination and rights of retention of the Lessee, unless the Lessee was not aware of the defect at the start of the Lease or it is not responsible for it and the Lessee can prove its unawareness or lack of responsibility.

 

	
(3)
	
If a defect occurs in the Leased Object after the start of the Lease and the Lessee, as a general rule, is entitled to warranty claims in relation to this defect, the provisions laid down by Sections 536 et seqq. of the German Civil Code will apply in accordance with this Lease.

 

	
(4)
	
If the Lessor delays rectifying the defect, the Lessee may rectify the defect itself and demand compensation for the expenditure incurred in this regard.

 

	
(5)
	
The Lessee will only be entitled to a rent reduction if the appropriate timeframe set for the Lessor by the Lessee within which to rectify defects has expired without action. Section 9 (2) of this Lease remains unaffected.

 

	
(6)
	
Claims for compensation by the Lessee, to the extent not excluded by this Lease, including claims arising from pre-contractual obligations and unlawful acts, can only be asserted if they are based on the intent or gross negligence of the Lessor or its vicarious agents.

 

	
(7)
	
All liability exclusions and limitations contained in this Lease also apply to the benefit of the organs, representatives and vicarious agents of the Lessor.

 

	
(8)
	
If the Lessor supplies energy and media within the framework of this Lease that are to be invoiced as operating costs, the following liability provision will apply regardless of the item supplied:

 

[***]

 

If the causes of an interruption or erratic supply are due to the electricity supply network operated by the Lessor as the operator of the electricity supply network for the Behringwerke Site, the Lessor is liable vis-à-vis the Lessee in accordance with Section 18 of the German Network Connection Ordinance.

 

Section 10

Maintenance, Cosmetic Repairs,

Structural and Technical Amendments

 

	
(1)
	
The allocation of obligations set out below is based on the circumstance that the Lessee is entitled to organise the internal fittings in the Leased Object at its own risk to the greatest extent in accordance with its operational requirements, and to take over the fixtures and 

Page 11 of 20

 

		
conversions of the previous lessees under its own responsibility. The allocation of obligations was also taken into consideration when calculating the rent excluding utilities.

 

The Lessor is only responsible for the maintenance, repair, upkeep, and inspection (hereinafter referred to as “Maintenance”) of the Leased Object within the defined limits pursuant to Section 1 of the Lease, namely the building envelope and the load-carrying components (“Roof and Structures”), and the installations, facilities, and fittings of the Leased Object described in more detail in Annex 2.1), Annex 2.2) (Additional Areas), and Annex 2.3), as well as for maintaining and repairing the circulation and ancillary use areas not included in the Lease (marked in “grey” in Annex 1.1), Annex 1.2), and Annex 1.3)) and any other communal technical installations, facilities and areas. This does not affect the exclusion of liability for initial defects pursuant to Section 9 of this Lease. Major maintenance and repair measures to be taken by the Lessor, i.e. such measures that may significantly affect the operations of the Lessee, will be agreed in good time with the Lessee beforehand. Prior agreement will not be required in the event of imminent danger.

 

Except in relation to the house connection, there is no obligation to maintain energy and media distribution infrastructure located within the building, as this infrastructure is not owned by the Lessor and does not form part of the Leased Object.

 

At its own expense, the Lessee is responsible for the maintenance, repair, upkeep and inspection of the facilities, installations, and fittings within Building H028, to the extent that these are not listed in Annex 2.1), 2.2), and 2.3) as part of the Leased Object but are located in the areas provided to the Lessee/in the spaces used by the Lessee. The Lessee is more specifically responsible for the maintenance, repair, upkeep and inspection of the fixtures and conversions carried out by the previous lessees and by the Lessee itself at its own expense. All works to maintain the operational readiness and operational safety of these facilities, installations, and fittings that are required by law and/or necessary according to the manufacturer’s instructions are the responsibility of the Lessee and must be carried out at its own expense.

 

Cosmetic repairs (e.g. replacing the wallpaper, paint and cleaning the carpets) in the Leased Object are the responsibility of the Lessee.

 

	
(2)
	
The Lessor is responsible for maintaining an appropriate physical appearance of the façade of the Leased Object. The Lessor will carry out modernisation work on the façade of Building H028, as described in Annex 9) to this Lease.

 

	
(3)
	
The Lessee is authorised to carry out structural or technical amendments to the Leased Object with the prior consent of the Lessor, to the extent not already acknowledged in Section 2 (2). For the Lessor to provide its consent, questions on the effects of the planned measures in terms of planning permission (including statics, fire protection, construction physics) and significance in terms of site development (including effects on the neighbourhood, environment and infrastructure) must be answered and a realistic assessment of the operational significance of the measures must be obtained. A joint approach is required in this regard.

 

If the Lessor approves structural and/or technical amendments, before the measures are implemented, by means of follow-up management, the type and extent of the amendments must be documented in a manner that complies with the written form requirement, as well as – where agreed – a waiver by the Lessor of the right to demand, at the end of the Lease, 

Page 12 of 20

 

restoration by the Lessee of the condition of the Leased Object prior to the structural and/or technical amendment and the obligation to maintain it.

 

	
(4)
	
In accordance with the areas key agreed pursuant to Annex 3.1) and 3.2), the Lessee will bear the costs of the adaptation of the technical building equipment of Building H028 by the Lessor, if and to the extent that adaptation is necessary, in order to allow simultaneous use of the building by the Lessee and other companies based in the building, regardless of which part of Building H028 the adaptation is carried out in.

 

Section 11

Company Sign

 

	
(1)
	
Taking the conditions on site into account, after agreement with the Lessor, the Lessee may affix its own company signs at its own expense only to the buildings or parts of buildings for which it has sole use. These costs will be at its own expense. If official permits are required for the affixing of these signs, the Lessee will obtain these and bear the associated costs.

 

The Lessee is responsible for fulfilling the public safety obligation for signs affixed by it.

 

	
(2)
	
(Hanging) internal communication and information boxes or boards installed outside of the areas for which the Lessee has sole use are subject to agreement between the Lessee and Lessor depending on the type of design, size and installation site.

 

	
(3)
	
If it is necessary to remove company signs pursuant to paragraphs (1) or (2) for works at the site or on the Leased Object, the Lessee will bear the costs of the removal, storage and reinstallation, including the resulting repairs to the facility required. At the end of the Lease, the Lessee must remove the company sign at its own expense and rectify any damage caused by the affixing, operation and removal.

 

	
(4)
	
If the Lessor installs standardised company signs, the Lessee may participate in the costs for affixing and maintaining these installations on a proportionate basis.

 

Section 12

Technical Building Services, Supply and Disposal

 

	
(1)
	
The Lessor is responsible for ensuring the proper technical connection of the Leased Object to the currently existing supply and disposal systems at the site. Except as provided for in Section 7 (5) concerning the supply of H028 South, the Lessee will be responsible for the supply of the Leased Object with the energy and media required for its use at its own expense by entering into separate energy supply contracts with the Lessor or third parties. The Lessee will be responsible for sufficiently heating the Leased Object using the air conditioning installations installed by it in the Leased Object for the purposes of production. Irrespective of their invoicing as operating costs or their supply within the framework of energy supply agreements, the delivery of energy and media takes place from the output terminal of the main distributor and from the first shut-off valve in the central energy room.

 

The Lease does not cover the infrastructure required for the onward transfer of energy and media in the building, such as electricity and water supply lines and these are not, therefore, included in Annex 2.1), Annex 2.2), and Annex 2.3). 

 

Page 13 of 20

 

This infrastructure is in the possession of [***] and the Lessee will agree with [***] on the usage and – if it rents all floors of Building H028 - transfer of this infrastructure outside the scope of this Lease. If this is not successful or if the infrastructure is not made available, this circumstance does not entitle the Lessee to terminate this Lease.

 

	
(2)
	
The Lessee will use the supply and disposal lines, e.g. for electricity, gas, nitrogen, compressed air, and water/wastewater only to the extent that no overload is caused. Any additional needs can be covered by the Lessee by extending the lines and necessary technical installations at its own expense after obtaining the Lessor’s prior written consent, which may only be refused for an important reason.

 

	
(3)
	
If it is necessary to convert devices or equipment, equipment parts and auxiliary equipment belonging to the Lessee because of a legally required change to the way energy is obtained, the costs of converting these devices or equipment, equipment parts and auxiliary equipment will be borne by the Lessee. Any claims for compensation by the Lessee and entitlements to rent reduction are excluded in this case.

 

Section 13

Insurance Policies

 

	
(1)
	
As at the handover date, the Lessor holds all risks property insurance, including building fire cover, as well as business liability insurance with a minimum coverage amount of EUR 10 million. The costs of these insurance policies are included (proportionately where necessary) in the operating costs pursuant to Section 7 of this Lease.

 

	
(2)
	
From the commencement of the Lease, the Lessee is obliged to take out a liability insurance policy which provides cover for rental damage with a minimum coverage amount of EUR 10 million, as well as all insurance policies necessary for the operations pursuant to Section 2 of this Lease. Comprehensive insurance coverage or policies that provide for an excess to be paid by the Lessee fulfil this requirement.

 

In the event of an increase to the previously insured risk, the Lessee must extend its insurance coverage without being requested to do so. The same applies to the Lessor’s insurance obligation under paragraph (1).

 

	
(3)
	
All insurance coverage must be maintained throughout the entire term of the Lease, either by continuing the relevant insurance policy or by taking out new comparable insurance policies. The determining factor is whether insurance coverage exists throughout the entire term of the Lease.

 

	
(4)
	
At the request of the other Party, each Party must produce certificates for the insurance policies to be taken out by it, which also state the amount of the excess and, when requested to do so at any time, provide evidence of payment of the premium where required.

 

	
(5)
	
Each Party undertakes to notify the other Party immediately if it becomes aware of missing or insufficient general or special insurance protection. This applies in particular in circumstances whereby the risk may be changed or increased, particularly where installations, structural amendments or changes of use take place.

 

	
(6)
	
The Lessee will notify the insurer and the Lessor immediately of any damage event and ensure that, to the extent possible and reasonable, no changes are made to the damage site before 

Page 14 of 20

 

		
the insurer’s inspection. Nevertheless, the Parties are obliged to take any measures required in order to reduce the damage or reduce consequential damage. The Parties will take these measures in agreement with each other and with the relevant insurer.

 

Page 15 of 20

 

Section 14

End of the Lease, Handover Obligation,

Restoration to the original condition

 

	
(1)
	
At the end of the Lease, the Lessee must return the Leased Object in accordance with the provisions of this Lease, swept clean and free from materials which may cause danger, significant disadvantages or significant pollution for individuals or the general public within the meaning of Section 3 of the German Federal Emissions Act (hereinafter referred to as “Contamination”), unless 

 

the Contamination was not caused by the Lessee or by previous lessees.

 

	
(2)
	
If there is Contamination in the Leased Object or in the parts of the building made available for use free of charge, the Lessee must also indemnify the Lessor fully during the term of the Lease if claims are made against the Lessor for investigations, decontamination or any other measures in relation to the Contamination, and it must also indemnify the Lessor against any claims from third parties in connection with such Contamination, unless the relevant Contamination was caused before 01.01.2005.

 

	
(3)
	
The Lessee is obliged to do the following at the end of the Lease:

	
 
	
—
	
have all facilities, installations, and fittings (even those installed in the Leased Object by previous lessees) located in Building H028 (including H030) in the areas used by the Lessee/in the spaces used by the Lessee professionally removed at its own expense, unless these are identified in Annex 2.1), Annex 2.2), and Annex 2.3) to the Lease as part of the Leased Object, including their connections to the Leased Object;

	
 
	
—
	
remove its movable fixtures at its own expense;

	
 
	
—
	
have all structural and technical amendments to the Leased Object (also to the extent carried out by previous lessees) professionally removed at its own expense and restore the structural and technical condition of the Leased Object identified in Annexes 1.1), 1.2), and 1.3) and in Annex 2.1), Annex 2.2), and Annex 2.3).

 

unless the Lessor has waived this obligation in writing in an amendment to this Lease.

 

	
(4)
	
If the Lessee does not fulfil its obligation to return the Leased Object pursuant to Section 14 of this Lease within the requisite period, then for each day of the delayed handover, it must pay the Lessor 1/30 of the most recently paid monthly advance payment for operating costs, plus the value added tax applicable at the time of payment.

 

The Lessor’s right to claim for compensation due to additional damage is not excluded.

 

	
(5)
	
The Parties will draw up a written handover report concerning the return of the Leased Object.

 

Section 15

Force majeure

 

If and to the extent that a Party is prevented from fulfilling its contractual obligations due to force majeure, it will be released from such obligations. It will notify the other Party immediately of the circumstances of the force majeure and make efforts to remedy these circumstances. If necessary and possible, the Parties will agree on the required adaptive measures.

Page 16 of 20

 

 

Section 16

Confidentiality

 

	
(1)
	
The Parties mutually undertake to maintain confidentiality in relation to all information that they obtain in relation to the conclusion of this Lease and its performance, including all economic framework conditions and the provisions laid down in this Lease, as well as any business and operational secrets that may become known. This means that the relevant information must not be disclosed to third parties without prior written consent of the other Party.

 

Excluded from this is the disclosure of information to third parties appointed by a Party for the implementation of the Lease, however only to the extent strictly necessary for the implementation of the Lease.

 

However, it is a requirement that such third parties (e.g. lawyers, tax advisors, brokers, experts, tradesmen, group companies, etc.) either are subject to professional secrecy obligations or are required in turn to maintain confidentiality.

 

The foregoing confidentiality obligation applies for a period of up to ten (10) years after the end of the Lease.

 

	
(2)
	
Excluded from the confidentiality obligation under paragraph (1) is information which the Parties have obtained prior to conclusion of the Lease and independent of the implementation of the Lease, and information that can be obtained by one of the Parties from generally accessible sources, without either Party having caused such information to be accessible through a breach of the confidentiality obligation.

 

The confidentiality obligation does not apply if one of the Parties discloses the necessary information as a result of a legal or official order or in legal proceedings to safeguard its legitimate interests. 

 

Section 17

Guarantees

 

	
(1) 
	
Within 14 days after the signing of this Lease, in order to guarantee all claims of the Lessor against the Lessee under this Lease, the Lessee will provide a guarantee that is directly enforceable on first request, issued by a German bank or public savings bank [Sparkasse] in accordance with the appended template (Annex 6), for an amount equal to three times the monthly rent excluding utilities at the start of the Lease, plus the advance payment for operating costs at the start of the Lease, plus value added tax.

 

	
(2)
	
If the Lessee does not provide a rental guarantee in the due and proper form within the agreed timeframe and after a deadline extension has been granted, the Lessor is authorised to extraordinarily terminate the Lease without notice.

 

	
(3) 
	
Six months after the end of the Lease, the Lessor will return the guarantee to the Lessee if and to the extent that the Lessor does not assert against the Lessee or the guarantor any claims arising from the Lease and secured by the guarantee.

 

Page 17 of 20

 

Section 18

Subletting, Transfer of Use

 

	
(1)
	
The Lessee may only transfer the use of the Leased Object to a third party and/or sublet it with the consent of the Lessor. The Lessor is obliged to permit a transfer of use to third parties if the third party is not a competitor of the Lessor and there is no other important reason for refusing permission. 

 

Section 19

Consideration, Averting Dangers

 

	
(1) 
	
The Parties agree that the foregoing provisions are only viable if they act considerately at the request of the other Party, taking into account other companies operating on the site and more specifically, undertake to seek amicable solutions to issues that cannot be foreseen and are not contractually provided for in detail.

 

	
(2)
	
This applies in particular to measures implemented by the Parties in accordance with the provisions laid down in this Lease under their own responsibility and at their own expense, and for official and other orders, which can only be complied with by mutual agreement.

 

	
(3)
	
In the event of imminent danger, the Lessee must comply with the instructions from the site security and fire services. It will also impose this obligation on its staff and on third parties appointed by it.

 

	
(4)
	
The attachment, placement or storage of items of any kind (boxes, goods, etc.) outside of the Leased Object, particularly on the shared traffic routes, is only permitted in the designated storage/parking areas.

 

	
(5)
	
The Lessee will receive a copy of the parking rules (Annex 7) and ensure that its employees and visitors comply with the parking rules and support the Lessor as far as possible in enforcing the parking rules.

 

Section 20

Entire Agreement, Written Form

 

	
(1)
	
This Lease contains all agreements made between the Parties. There are no additional agreements, ancillary agreements, or undertakings. If, contrary to the previous sentence, additional agreements, ancillary agreements, or undertakings do exist, these are hereby rescinded.

 

	
(2)
	
Amendments and supplements to this agreement and its annexes, and all declarations of intent under this Lease, must be made in writing in order to be valid. This also applies in the event of an amendment to this written form clause.

 

	
(3)
	
The Parties undertake not to terminate this Lease early by invoking any non-compliance with the written form requirement. This applies not only to the conclusion of this Lease, but also to any addenda, amendments or supplements hereto. If the written form requirement is not complied with for amendments and supplements, the Parties further undertake to rectify this immediately.

 

	
(4)
	
The Lease is drawn up in two counterparts; each Party receives one copy thereof.

Page 18 of 20

 

		

 

Section 21

Entry to the Leased Object, Public Safety Obligation, Annexes,

Partial Invalidity, Place of Jurisdiction, Competition Clause

 

	
(1)
	
The Lessor, its representatives, experts, and interested parties may enter the Leased Object after providing sufficient notice and during business hours in order to check its condition for re-letting or sale purposes or for another important reason, subject to agreement and taking the legitimate interests of the Lessee into consideration.

 

If regulatory requirements apply to parts of the Leased Object (for example GMP rules), entry by the Lessor is only authorised if these requirements are complied with. The Lessee will provide the Lessor with comprehensive information on the rules to be complied with and the necessary measures in good time.

 

In the event of imminent danger, they must be granted access at any time of day or night. In this case, in the event of absence, the Lessee must provide the corresponding access options or leave keys in an accessible place known to the Lessor.

 

If required, the Lessor and its appointed parties are also authorised to enter the Leased Object at any time of day or night in agreement with the Lessee (the agreement must be documented for example by providing a corresponding access authorisation card) in order to access energy rooms, communications hubs, main and single-floor distribution boards for telephones, main and single-floor fire alarm distribution boards, battery facilities and electroacoustic installations, as well as any other premises used to supply the Leased Object.

 

When entering the Leased Object, the Lessor must give the necessary and requested consideration to the Lessee’s operations.

 

	
(2)
	
The Lessee is subject to the public safety obligation within the leased areas and technical areas used by it alone, to the extent that these are indeed used by the Lessee alone. If technical areas are used by both the Lessee and Lessor (Section 1 (3) of the Lease), both parties are equally bound by the public safety obligation and are jointly and severally liable vis-à-vis third parties in the event of a breach of the public safety obligation.

 

	
(3)
	
All annexes constitute a component of this Lease. 

 

	
(4)
	
On the date on which it comes into force, this Lease replaces all existing oral and/or written ancillary agreements between the parties concerning the leasing of areas and spaces in Building H028, therefore also the Lease concerning H028 North of 25.06.2016, together with its amendments.

 

	
(5)
	
This Lease is independent of further leases entered into between the contractual parties.

 

	
(6)
	
The laws of the Federal Republic of Germany apply to this Lease and the tenancy provided for therein. If any translations of the Lease are created, the German version will prevail.

 

 

	
(7) 
	
In relation to any disputes resulting from this Lease, the courts of Marburg will have jurisdiction, as far as legally permitted.

 

Page 19 of 20

 

	
(8)
	
If a provision of this agreement or a future new provision is fully or partially ineffective or unenforceable, or loses its validity or enforceability at a later date, or if a loophole is discovered in this agreement, this will not affect the validity of the other provisions. To replace the ineffective or unenforceable provisions or to close the loophole, an appropriate provision will be agreed on in the proper form, which, as far as legally permissible, comes closest to what the Parties intended when entering into the Lease, or to what they would have wanted  in accordance with the purpose of the agreement if they had considered the matter.

 

	
(9) 
	
There is no competition clause.

 

	
(10)
	
The following are annexes to this agreement:

 

		
	
Annex 1.1)
	
Plans for the Leased Object, (H028 North, H030 and H028 South without Additional Areas, i.e. only floors 1 - 2)

	
Annex 1.2)
	
Plans for the Leased Object (only Additional Areas, i.e. only H028 South, floors 1 - 2)

	
Annex 1.3)
	
Plans for the Leased Object after leasing of the Additional Areas (H028 North, H030 and H028 South including Additional Areas)

	
Annex 1.4)
	
Site plan

	
Annex 2.1)
	
List of installations, facilities, and fittings for the Leased Premises (H028 North, H030, and H028 South without Additional Areas, i.e. without floors 1  - 2)

	
Annex 2.2)
	
List of installations, facilities, and fittings for the Leased Premises (only Additional Areas, i.e. only H028 South, floors 1 - 2)

	
Annex 2.3)
	
List of installations, facilities, and fittings for the Leased Premises (H028 North, H030, H028 South, floors 1 - 6)

	
Annex 3.1)
	
Lessee’s share of the total area for the building, without Additional Areas

	
Annex 3.2)
	
Lessee’s share of the total area for the building, with Additional Areas

	
Annex 4.1)
	
Net rent excluding utilities, without Additional Areas, from 01.01.2020

	
Annex 4.2)
	
Net rent excluding utilities, with Additional Areas, from 01.01.2024

	
Annex 4.3)
	
Net rent excluding utilities, with Additional Areas, from 01.01.2025

	
Annex 5.1)
	
Services covered by operating expenses H028 North, H028 South (without floors 1-2 H028 South), and H030, i.e. including energy and media supply

	
Annex 5.2)
	
Services covered by operating expenses H028 North, H028 South (with floors 1-2 H028 South), and H030, i.e. without energy and media supply

	
Annex 5.3)
	
Initial advance payment for operating expenses

	
Annex 6)
	
Rental guarantee template

	
Annex 7)
	
General entrance and parking rules for the Behringwerke Site

	
Annex 8)
	
List of the goods only to be stored in Building H030

	
Annex 9)
	
Description of the façade renovation

 

		
	
Marburg, 25.07.19
	
Marburg, 25.07.2019

	
 
	
 

	
Pharmaserv GmbH
	
Novartis Manufacturing GmbH

 

 

Page 20 of 20

 

 

Appendix 1.1)
[***]

 

 

 

As of: 26.06.2019

Page 1 of 7

 

Appendix 1.1)
[***]

 

 

 

 

 

As of: 26.06.2019

Page 2 of 7

 

Appendix 1.1)
to the Lease concerning areas and spaces in buildings H028 and H030
between Pharmaserv GmbH
and Novartis Manufacturing GmbH

 

 

 

 

 

 

 

 

 

As of: 26.06.2019

Page 3 of 7

 

Appendix 1.1)
[***]

 

 

 

 

As of: 26.06.2019

Page 4 of 7

 

Appendix 1.1)
[***]

 

 

 

 

 

 

As of: 26.06.2019

Page 5 of 7

 

Appendix 1.1)
[***]

 

 

 

 

 

 

 

 

 

 

As of: 26.06.2019

Page 6 of 7

 

Appendix 1.1)
[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of: 26.06.2019

Page 7 of 7

 

 

Appendix 1.2)
[***]

 

 

 

 

As of: 26.06.2019

Page 1 of 2

 

Appendix 1.2)
[***]

 

 

 

 

 

As of: 26.06.2019

Page 2 of 2

 

 

Appendix 1.3)
[***]

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Appendix 1.3)
[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Appendix 1.4

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

		
	
BILINGUAL KEY

	
DE
	
EN

	
Anlage 1.4)
zum Mietvertrag über Flächen und Räume in Gebaüde H028 zwischen Pharmaserv GmbH und Novartis Manufacturing GmbH
	
Appendix 1.4)
to the lease concerning areas and spaces in building H028 between Pharmaserv GmbH and Novartis Manufacturing GmbH

	
Gebaüde H034
	
Building H034

	
Gebaüde H030
	
Building H030

	
Gebaüde H033
	
Building H033

	
Lageplan
	
Site plan

	
Abstellfläche für Abfallcontainer H028 Nord
	
Storage area for waste container(s) H028 north

	
H028 Nord
	
H028 north

	
Gebaüde H028 gesamt
	
Building H028 entire

	
H028 Süd
	
H028 south

	
Abstellfläche für Abfallcontainer H028 Süd
	
Storage area for waste container(s) H028 south

	
Gebaüde H021
	
Building H021

	
Stand: 26.06.2019
	
As of: 26.06.2019

	
Seite 1 von 1
	
Page 1 of 1

 

 

 

Appendix 2.1

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

 

	
Pharmaserv GmbH
	
As at: 26/06/2019

	
SOM-FAC-REM-KIM
	
Page 12 of 5

 

Appendix 2.1

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, (H030)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

 

	
Pharmaserv GmbH
	
As at: 26/06/2019

	
SOM-FAC-REM-KIM
	
Page 13 of 5

 

Appendix 2.1

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 3-6)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 3-6)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***]
	
[***]
	
[***]
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
[***] 
	
 

 

 

 

	
Pharmaserv GmbH
	
As at: 26/06/2019

	
SOM-FAC-REM-KIM
	
Page 14 of 5

 

Appendix 2.2

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-2)

 

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
[***]

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***]
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 15 of 2

Appendix 2.2

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-2)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
[***] 
	
 

 

 

 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 16 of 2

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)

 

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
[***] 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

 

 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

 

 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 17 of 5

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (North)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***]
	
 
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
[***] 
	
[***] 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 18 of 5

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

	
List of Fixtures, Equipment and Fittings of the Leased Property, (H030)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
[***] 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***] 
	
[***] 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 19 of 5

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

	
List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-6)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 

List of Fixtures, Equipment and Fittings of the Leased Property, Building H028 (South, levels 1-6)

	
Category
	
Leased Object

(Fixtures, Equipment and Fittings)
	
Notes
	
Technical Identification of the Equipment

 

No entry – for all parts of the equipment

Entry – only for the part of equipment stated
	
Room

 

Location of the fixture/equipment
	
Performance data / properties

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 

	
 
	
[***]
	
[***]
	
 
	
[***]
	
 

 

 

Pharmaserv GmbHAs at: 26/06/2019

SOM-FAC-REM-KIMPage 20 of 5

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 3.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
 

Proportion of the total area allocated to the Lessee 

H030 Building 

 

 

 

	
1. The total area of the H030 Building is
	
13,217.08 m2

 

	
2. The proportion of the total area of the H028 Building (H028 North entire building and H028 South 3rd - 6th floors) allocated to the Lessee is 

 
	
 

10,267.65 m2

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 21 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 3.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
 

Proportion of the total area allocated to the Lessee 

H030 Building 

 

 

 

	
1. The total area of the H030 Building is
	
86.54 m2

 

	
2. The proportion of the total area of the H030 Building allocated to the Lessee is 
	
86.54 m2

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 22 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 3.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
 

Proportion of the total area allocated to the Lessee 

H028 Building 

 

 

 

	
1. The total area of the H028 Building is
	
13,217.08 m2

 

	
2. The proportion of the total area of the H028 Building (H028 North entire building and H028 South entire building) allocated to the Lessee is 

 
	
 

13,217.08 m2

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 3.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
 

Proportion of the total area allocated to the Lessee 

H030 Building 

 

 

 

	
1. The total area of the H030 Building is
	
86.54 m2

 

	
2. The proportion of the total area of the H030 Building allocated to the Lessee is 
	
86.54 m2

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Basic rent (graduated rent) euros/month net

H028 Building excluding additional space with effect from 01.07.2019

(H028 North, H028 South 3rd – 6th Floors) 

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***]

	
01.01.2020 - 31.12.2020
	
€ [***]

	
01.01.2021 - 31.12.2021
	
€ [***] 

	
01.01.2022 - 31.12.2022
	
€ [***] 

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***]

	
01.01.2028 - 31.12.2028
	
€ [***]

	
01.01.2029 -31.12.2029
	
€ [***]

	
01.01.2030 - 31.12.2030
	
€ [***]

	
01.01.2031 - 31.12.2031
	
€ [***]

	
01.01.2032 - 31.12.2032
	
€ [***]

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***] 

 

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Basic rent (graduated rent) euros/month net

H030 Building with effect from 01.07.2019

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***] 

	
01.01.2020 - 31.12.2020
	
€ [***] 

	
01.01.2021 - 31.12.2021
	
€ [***] 

	
01.01.2022 - 31.12.2022
	
€ [***] 

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***] 

	
01.01.2028 - 31.12.2028
	
€ [***]

	
01.01.2029 -31.12.2029
	
€ [***]

	
01.01.2030 - 31.12.2030
	
€ [***] 

	
01.01.2031 - 31.12.2031
	
€ [***] 

	
01.01.2032 - 31.12.2032
	
€ [***] 

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***]

 

 

 

 

 

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Basic rent (graduated rent) euros/month net

H028 Building excluding additional space with effect from 01.01.2024

(H028 North, H028 South 3rd – 6th Floors, entire H028 South with effect from 01.01.2024) 

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***] 

	
01.01.2020 - 31.12.2020
	
€ [***] 

	
01.01.2021 - 31.12.2021
	
€ [***] 

	
01.01.2022 - 31.12.2022
	
€ [***] 

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***] 

	
01.01.2028 - 31.12.2028
	
€ [***] 

	
01.01.2029 -31.12.2029
	
€ [***] 

	
01.01.2030 - 31.12.2030
	
€ [***] 

	
01.01.2031 - 31.12.2031
	
€ [***] 

	
01.01.2032 - 31.12.2032
	
€ [***] 

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***] 

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Basic rent (graduated rent) euros/month net

H030 Building with effect from 01.07.2019

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***] 

	
01.01.2020 - 31.12.2020
	
€ [***] 

	
01.01.2021 - 31.12.2021
	
€ [***]

	
01.01.2022 - 31.12.2022
	
€ [***]

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***] 

	
01.01.2028 - 31.12.2028
	
€ [***] 

	
01.01.2029 -31.12.2029
	
€ [***] 

	
01.01.2030 - 31.12.2030
	
€ [***] 

	
01.01.2031 - 31.12.2031
	
€ [***] 

	
01.01.2032 - 31.12.2032
	
€ [***] 

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***] 

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.3)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Basic rent (graduated rent) euros/month net

H028 Building excluding additional space with effect from 01.01.2025

(H028 North, H028 South 3rd – 6th Floors, entire H028 South with effect from 01.01.2025) 

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***] 

	
01.01.2020 - 31.12.2020
	
€ [***] 

	
01.01.2021 - 31.12.2021
	
€ [***] 

	
01.01.2022 - 31.12.2022
	
€ [***] 

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***] 

	
01.01.2028 - 31.12.2028
	
€ [***] 

	
01.01.2029 -31.12.2029
	
€ [***] 

	
01.01.2030 - 31.12.2030
	
€ [***] 

	
01.01.2031 - 31.12.2031
	
€ [***] 

	
01.01.2032 - 31.12.2032
	
€ [***] 

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 4.3)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
	
 

Basic rent (graduated rent) euros/month net

H030 Building with effect from 01.07.2019

 

 

 

	
Lease period
	
Euros/month

 

	
01.07.2019 – 31.12.2019
	
€ [***] 

	
01.01.2020 - 31.12.2020
	
€ [***] 

	
01.01.2021 - 31.12.2021
	
€ [***] 

	
01.01.2022 - 31.12.2022
	
€ [***] 

	
01.01.2023 - 31.12.2023
	
€ [***] 

	
01.01.2024 – 31.12.2024
	
€ [***] 

	
01.01.2025 - 31.12.2025
	
€ [***] 

	
01.01.2026 - 31.12.2026
	
€ [***] 

	
01.01.2027 - 31.12.2027
	
€ [***] 

	
01.01.2028 - 31.12.2028
	
€ [***] 

	
01.01.2029 -31.12.2029
	
€ [***] 

	
01.01.2030 - 31.12.2030
	
€ [***] 

	
01.01.2031 - 31.12.2031
	
€ [***] 

	
01.01.2032 - 31.12.2032
	
€ [***] 

	
01.01.2033 - 31.12.2033
	
€ [***] 

	
01.01.2034 - 31.12.2034
	
€ [***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 5.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
1.
	
[***]

 
	
 

	
2.
	
[***]

 
	
 

	
3.
	
[***]

 
	
 

	
4.
	
[***]

 
	
 

	
5
	
[***]

 
	
 

	
6.
	
[***]

 
	
 

	
7.
	
[***]

 
	
 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 5.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
8.
	
[***]

 
	
[***]

	
9.
	
[***]

 

	
[***]

 
	
[***]

	
[***]

 
	
[***]

	
[***]

 
	
[***]

	
[***]

 
	
[***]

	
[***]

 
	
[***]

	
[***]

 
	
[***]

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 5.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
 
	
[***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 3 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 5.1)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
10.
	
[***]

 

	
[***]

 

	
11.
	
[***]

 

	
12.
	
[***]

 

	
13.
	
[***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 4 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 5.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
1.
	
[***]

 
	
 

	
2.
	
[***]

 
	
 

	
3.
	
[***]

 
	
 

	
4.
	
[***]

 
	
 

	
5.
	
[***]

 

	
[***]

 
	
[***]

	
[***]

 
	
[***]

	
[***]

 
	
[***] 

	
[***]

 
	
[***]

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 5.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

 

	
 
	
5.5

 
	
[***]

	
 
	
5.6

 
	
[***]

	
 
	
[***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 5.2)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

	
Service charges

as defined in Article 7 of the Lease are

 
	
 

Notes 

 

	
6.
	
[***]

 

	
[***]

 

	
7.
	
[***]

 

	
8.
	
[***]

 

	
9.
	
[***]

 

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 3 of 4

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 5.3)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
	
 

Advance payment of service charges euros/month net

H028 Building

 

 

	
€ [***]

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 5.3)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

 

	
 

Advance payment of service charges euros/month net

H030 Building

 

 

	
€ [***]

 

 

	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SOM-FAC-REM-KIM
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 6)

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

 

 

Standard

 

 

Rent guarantee

 

 

Novartis Manufacturing GmbH

Emil-von-Behring-Strasse 76

35041 Marburg 

- hereinafter called “Lessee” -

 

and

Pharmaserv GmbH

Emil-von-Behring-Strasse 76

35041 Marburg

- hereinafter called “Lessor” –

 

concluded on ___________ a Lease for Commercial Premises on the site in Emil-von-Behring-Strasse 76 in 35041 Marburg (leased premises: space and premises in the H028 Building). The provision of a guarantee by the Lessee from a bank approved for business transactions in the EU had been agreed to ensure the performance of the contractual obligations of the Lessee.

 

With this proviso, we 

 

_______________ [Bank],

 

herewith assume with regard to the Lessor, including its successors (hereinafter Beneficiary in each case) all existing and future claims, including conditional and/or limited claims, which the Beneficiary has or will have against the Lessee under or in connection with the aforementioned Lease (including claims for damages for breach of duty, non-performance or in lieu of performance, 

 

	
FOR-KIM-0026-06
	
Page 1 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

claims in respect of delay or unjust enrichment), with the unconditional, unlimited and irrevocable guarantee up to an amount that corresponds to three times the applicable monthly rent inclusive of service charges plus value added tax (“maximum amount”). The aforementioned basis of calculation currently establishes a maximum amount of 

 

€ [***]

(in words: 

[***]).

 

The assumption of claims entails waiving the pleas of contestability and set-off, unless the counterclaim for set-off made by the Lessee is either undisputed or expressly acknowledged or legally binding, and waiving the plea that the creditor first proceeds against the debtor (Section 771 German Civil Code). This guarantee applies regardless of any other guarantees and other collateral, which are provided by a third party as additional security for claims by the Beneficiary. The creation of a collective guarantee (joint and several liability) pursuant to Section 769 German Code is thus excluded. 

 

We will make a payment to the Beneficiary on receipt of the first written request from the Beneficiary and may only be called upon to make payment of money. The guarantee expires when this document is returned to us by the Beneficiary.

 

The laws of the Federal Republic of Germany shall apply to this guarantee. If this guarantee is translated, the German version shall prevail. The courts in Marburg shall have exclusive jurisdiction to hear any legal disputes that may arise out of this guarantee.

 

 

______________, on _________________

 

______________________________

 

 

 

	
FOR-KIM-0026-06
	
Page 2 of 2

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 7)

[***] 

 

 

 

		
	
Page 2 of 10
	
Parking Regulations_Site_Behringwerke_2017.docx

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

[***]

 

		
	
Page 3 of 10
	
Parking Regulations_Site_Behringwerke_2017.docx

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

[***]

 

 

   

 

 

		
	
Page 4 of 10
	
Parking Regulations_Site_Behringwerke_2017.docx

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 8)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

	
 

Inventory H030 Building

 

 

	
Material
	
Substances

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

		
	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SO-FAC-REM-KIM
	
Page 5 of 6

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 9)

 

to the Lease of Space and Premises in the H028 and H030 Buildings

between Pharmaserv GmbH

and Novartis Manufacturing GmbH 

 

	
 

Scheduled works on the leased premises 

excluding the H030 Building

 

 

Objectives

 

[***]

 

 

 

		
	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SO-FAC-REM-KIM
	
Page 1 of 6

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 9)

[***]

 

[***]

 

		
	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SO-FAC-REM-KIM
	
Page 2 of 6

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

 

Annex 9)

[***] 

 

[***]

[***]

 

 

		
	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SO-FAC-REM-KIM
	
Page 3 of 6

 

Appendix 2.3

to the Lease for areas and rooms in the buildings H028 and H030

between Pharmaserv GmbH

and Novartis Manufacturing GmbH

Annex 9)

[***]

 

		
	
Pharmaserv GmbH
	
As at: 26.06.2019

	
SO-FAC-REM-KIM
	
Page 4 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]